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Abstract 
Glioblastoma multiforme (GBM) is the most common and aggressive primary 
brain tumor. The current standard-of-care treatment including surgery, radiation and 
temozolomide (TMZ) chemotherapy does not prolong the survival satisfactorily. Here 
we have tested the feasibility, efficacy and safety of a potential gene therapy approach 
using AAV as gene delivery vehicle for treatment of GBM. 
Interferon-beta (IFN is a cytokine molecule also having pleiotropic anti-
cancerous properties.  Previously it has been shown by our group that AAV mediated 
local (intracranial) gene delivery of human IFN (hIFN) could be an effective 
treatment for non-invasive human glioblastoma (U87) in orthotopic xenograft mouse 
model. But as one of the major challenges to treat GBM effectively in clinics is its 
highly invasive property, in the current study we first sought to test the efficacy of our 
therapeutic model in a highly invasive human GBM (GBM8) xenograft mouse model. 
One major limitation of using the xenograft mouse model is that these mice are 
immune-compromised. Moreover, as IFN does not interact with cross-species 
receptors, the influence of immune systems on GBM remains largely untested. 
Therefore to test the therapeutic approach in an immune-competent mouse model, we 
next treated a syngeneic mouse GBM model (GL261) in an immune-competent mouse 
(C57B6) with the gene encoding the species-matched IFN mIFN. We also tested if 
combination of this IFN gene therapy with the current standard chemotherapeutic 
drug (TMZ) is more effective than any one of the therapeutic modes alone. Finally, we 
tested the long term safety of the AAV-mIFN local gene therapy in healthy C57B6 
mice. 
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Next, we hypothesized that global genetic engineering of brain cells expressing 
secretory therapeutic protein like hIFN could be more beneficial for treatment of 
invasive, migratory and distal multifocal GBM. We tested this hypothesis using 
systemic delivery of AAV9 vectors encoding hIFN gene for treatment of GBM8 tumor 
in nude mice. 
Using in vivo bioluminescence imaging of tumor associated firefly luciferase 
activity, long term survival assay and histological analysis of the brains we have 
shown that local treatment of AAV-hIFN for highly invasive human GBM8 is 
therapeutically beneficial at an early growth phase of tumor. However, systemic 
delivery route treatment is far superior for treating multifocal distal GBM8 tumors. 
Nonetheless, for both delivery routes, treatment efficacy is significantly reduced when 
treated at a later growth phase of the tumor. 
 In syngeneic GL261 tumor model study, we show that local AAV-mIFN gene 
therapy alone or in combination with TMZ treatment can provide significant survival 
benefit over control or only TMZ treatment, respectively. However, the animals 
eventually succumb to the tumor. Safety study in the healthy animals shows significant 
body weight loss in some treatment groups, whereas one group shows long term 
survival without any weight loss or any noticeable changes in the external 
appearances. However, histological analysis indicates marked demyelinating 
neurotoxic effects upon long term exposures to mIFN over-expressions in brain. 
Overall, we conclude from this study that AAV-IFN gene therapy has great 
therapeutic potential for GBM treatment in future, but the therapeutic window is small 
and long term continuous expression could have severe deleterious effects on health.  
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Glioblastoma and the challenges for its treatment 
Humans have been fighting different forms of cancers since time immemorial. 
From having limited options based on traditional herbal medicines, primitive surgeries, 
diet regimens and palliative care to the modern day treatments with state-of-the-art 
surgeries and equipment, advanced chemotherapy, radiotherapy and more recently, 
immunotherapy, gene and cell therapy_ biomedical innovations have come a long 
way. Today’s advanced methods of cancer screening, such as colonoscopy, PSA test, 
mammography and pap tests help early diagnosis and improve the chance of success 
in cancer treatments. Many of the cancers like breast cancer, melanoma, prostate 
cancer or cervical cancer, when diagnosed at an early stage, are effectively treatable 
today. Sophisticated maintenance care has improved the survival as well as quality of 
life for patients suffering from many other cancers. This gives hope and 
encouragement to the scientific community and society as a whole to sustain the 
endeavor of finding new avenues to fight lethal and hitherto untreatable cancers.  
Glioblastoma multiforme, or simply called glioblastoma (GBM), is a malignant 
brain cancer and one that still remains beyond our ability to treat effectively. GBM is 
the most aggressive form (World Health Organization grade IV)1 of glial cell 
malignancy and also the most common form of primary brain tumor2. Every year there 
are about 10,000 new cases of GBM in the United States3. The standard-of-care 
involves surgical resection, followed by radiotherapy along with concomitant and 
adjuvant chemotherapy with temozolomide3. Unfortunately, even after providing the 
best of the standard care, the survival benefit is minimal for GBM patients. The 
xx 
 
 
median survival in patients is only about 15-17 months4 post diagnosis and 5 year 
survival5 is less than 10%.  
This dismal prognostic condition remains for several reasons, despite the 
advancement in the surgical techniques. One of the primary reasons is the ability of 
these tumors to recur after surgery. The recurrence is caused partly because of the 
inability to completely remove the tumors during surgery and partly due to the fact that 
often these tumors are radio- and chemo-resistant6-8. The reason why these tumors 
are almost impossible to be completely resected lies within the very properties of 
these cells. GBM cells are highly invasive and migratory in nature9. They show 
extensive single cell infiltration to far distant locations in the brain from the main tumor 
mass. These single cell infiltrates are impossible to detect in MRI scans and also are 
indistinguishable from the surrounding normal brain tissue macroscopically. Thus 
complete surgical resection is not possible. These residual tumor cells give rise to 
recurrent tumors that are often more resistant to radio- and chemotherapy, eventually 
causing death in patients9 (Figure I). Therefore active research is ongoing in search of 
new modalities to treat GBM. Some of the promising approaches are described below 
primarily focusing on virus and viral vector mediated cancer therapies and clinical 
trials for GBM in particular. 
Oncolytic virotherapy 
The concept of virotherapies for cancer has its origin in the mid-1800s with 
several anecdotal reports of tumor regression in patients after acquiring natural virus 
infections10. For example, in one case in 1912, a woman with cervical cancer reported 
regression of tumor upon receiving attenuated rabies virus vaccine11. However, early  
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Figure I: Invasive and migratory properties of glioblastoma make complete surgical resection 
impossible. The large tumor mass is removed during surgery. But the single tumor cells infiltrations 
that often migrate long distances from the main tumor mass in the brain remain undetected. These 
residual tumors later cause recurrence and eventually result in death of the patients.   
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attempts of body fluid transfusion from virus infected patients to cancer patients 
did not show much therapeutic promise10, which may have been caused by 
neutralization of viruses through the host immune response11. Further attempts were 
made in 1950s and 1960s to make viruses more tumor-specific, but with limited 
success at that time. Later, the advent of reverse genetics and advanced molecular 
biology tools led to a resurgence of interest in the 1990s and promising results were 
obtained both in cell culture and animal models10,11. 
The mechanism of oncolytic virotherapy (OV) mediated cancer treatment 
involves two major processes. The first one is direct tumor cell lysis due to viral 
replication followed by release of virus from the lysed cells, which can then infect the 
neighboring tumor cells and repeat this cycle12. This cycle of infection, replication and 
lysis may continue and amplify until the immune response stops it, or there is a lack of 
susceptible cells. An equally important anti-tumor mechanism of oncolytic viruses is 
mediated by stimulation of innate and tumor-specific immune response13,14. Tumor-
associated antigens (TAA) are released from tumor cells upon their lysis by viruses. 
These TAA can induce adaptive tumor-specific immune responses which can then act 
against distant tumors that are not exposed to virus (distant bystander effect). 
Moreover, the released cytokines (like type I interferons, interleukin-12, tumor necrosis 
factor- etc.), viral components and additional cellular components (like heat shock 
proteins, ATP, uric acid etc.) may promote CD4+ and CD8+ T cells and natural killer 
cells. These cytokines, PAMPs (‘pathogen-associated molecular pattern signals’) and 
DAMPs (‘danger associated molecular pattern signals’) also help maturation of 
antigen presenting cells (like dendritic cells)13,14. These immune components play very 
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important anti-tumor roles. However, immune response triggered naturally by viral 
infection may pose a hurdle to this approach if the oncolytic viruses are neutralized 
and cleared by the immune system before the tumors are killed.  
Several clinical trials with OV have been carried out in the last 15 years and 
many are also currently ongoing (ClinicalTrial.gov). Adenovirus, herpes simplex virus 
(HSV), vaccinia virus, reovirus and poliovirus are some of the type of viruses currently 
being tested in clinical trials for a wide variety of cancers that include head and neck 
cancer, pancreatic cancer, lung cancer, breast cancer, colorectal cancer, 
hepatocellular carcinoma, melanoma, ovarian cancer and gliomas. Recently (on 
October 27, 2015) the FDA approved HSV-based IMLYGIC (Talimogene 
Laherparepvec, Amgen) as the first OV in the US for recurrent melanoma.  
Along with other cancers, a number of OV clinical trials were also initiated for 
treatment of malignant glioma in the last decade. Some of the key trials of the last 
decade are shown in Table-I. The major challenges of an OV approach include 
specific cancer cell targeting, evading the virus-neutralizing immune response while 
still achieving the anti-tumor immune response, proper distribution of the delivered 
virus and avoiding virus related adverse effects. Even though no serious virus related 
adverse events were reported in the results from the early phase clinical trials for 
malignant gliomas, the therapeutic benefits were modest at best11,15,16. However, as 
these were primarily safety studies, dosing regimens were conservatively planned and 
could be optimized to improve therapeutic outcomes.   
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Table-I: Oncolytic virotherapies for GBM in clinical trial 
(Source: ClinicalTrials.gov and published literature11,13,17) 
Drug name Virus type Modification  Manufacturer or 
Sponsor  
Clinical 
trial phase  
ClinicalTrials.gov 
Identifier or PMID 
DNX-2401 Adenovirus Delta24-RGD 
insertion 
DNAtrix Ib, II NCT02197169; 
NCT01956734; 
NCT02798406 
Onyx-015 Adenovirus E1B-55k-E3B del Onyx 
Pharmaceuticals 
I PMID: 15509513 
G207 Herpesvirus ICP34.5 deletion, 
UL39 disruption 
MediGene I, II NCT00028158; 
NCT00157703 
HSV-1716 Herpesvirus ICP34.5 deletion Pediatric Brain 
Tumor Consortium 
I NCT02031965 
OrienX010 Herpesvirus ICP34.5 deletion, 
ICP47 deletion, 
GM-CSF insertion
OrienGene 
Biotechnology 
I NCT01935453 
Reolysin  Reovirus None Oncolytics Biotech I/II NCT00528684 
PVSRIPO Poliovirus IRES replaced 
with HRV2 IRES 
in attenuated 
(Sabin) strain 
Darell D. Bigner, 
Duke University 
Medical center 
I NCT01491893 
MV-CEA Measles virus Human 
carcinoembyonic 
antigen inserted 
Mayo Clinic I NCT00390299 
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Suicidal gene therapy 
 Another promising cancer therapy approach is ‘suicidal gene therapy’ (SGT). 
This approach involves transferring a cytotoxic gene to cancer cells using viral or non-
viral gene delivery vehicles. The most commonly used SGT method comprises 
transferring a gene to tumor cells where it produces a heterologous enzyme, which 
can then convert a non-toxic prodrug to an active cytotoxic drug to kill the tumor cells.  
The concept was first demonstrated 30 years ago when Moolten showed that 
expressing the herpes simplex virus thymidine kinase (HSV-tk) gene in cancer cells 
chemo-sensitized them to a prodrug18. HSV-tk gene converts the prodrug ganciclovir 
(GCV) to GCV-monophosphate, which is then converted to GCV-triphosphate by the 
tumor cell kinases. GCV-triphosphate induces apoptosis in the tumor cells. Reports 
show that this can also induce tumor-specific cytotoxic T cell response, leading to a 
distant bystander effect besides gap junction mediated local bystander effect19 
resulting in long term therapeutic benefit in animal models20. This approach was first 
used for glioblastoma in culture and in a mouse model in 1991 by Ezzedine et al.21. In 
a similar mechanism cytosine deaminase (CD) derived from Escherichia coli or 
Saccharomyces cerevisiae can convert a prodrug called 5-Fluorocytosine (5-FC) to 
the active drug 5-Fluorouracil (5-FU) that kills tumor cells22. These two are the most 
extensively studied suicide gene therapies. However, there are other suicide 
gene/prodrug combinations that have been tested, such as, cytochrome P450 (with 
prodrugs cyclophosphamide or ifosfamide), nitroreductase (with CB1954), Purine 
nucleoside phosphorylase (with MeP-dR or F-araA) and carboxypeptidase A1 (with 
MTX--peptides).23    
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Non-viral vehicles used for suicide gene delivery include cationic liposomes, 
cationic polymer, immuno-liposomes, exosomes, polyethylene glycol-conjugated 
nanoparticles etc. Even though non-viral vectors are generally considered to be safer 
than their viral counterparts, the gene transfer efficiency is lower. A majority (almost 
70%) of the overall current gene therapy clinical trials involve viral vectors and cancer 
gene therapy is no exception. Viral vectors used for cancer gene therapy are 
commonly derived from retroviruses, lentivirus, vaccinia virus, herpes simplex virus, 
adenovirus and adeno-associated virus22,24-26.  
A number of clinical trials have been carried out that involved SGT approach for 
treatment of different cancers including prostate 27,28, liver (hepatocellular 
carcinoma)29, head and neck 30, glioblastoma (Table II) and others. Some of the 
challenges that remain for this modality to achieve expected success include 
frequently found resistance of GBM cells to activated drugs, specific targeting, and 
achieving the desired distribution of suicide genes and prodrugs. Nonetheless, SGT is 
the most common approach among the currently running gene therapy clinical trials 
for GBM in the US (ClinicalTrials.gov). The results so far mostly demonstrate safety of 
the treatments in early phase trials (Table II). Recent trials using adenovirus/HSV-tk 
with valacyclovir, or involving retrovirus/CD and 5-FC showed favorable therapeutic 
outcomes31,32. To improve our understanding of the therapeutic effects from this 
approach, we have to wait for more advanced phase clinical trials.  
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Table II: Suicidal gene therapy for GBM in clinical trials 
(Source: ClinicalTrial.Gov and published reports31,33-35) 
 
 
 
  
Delivery vehicle/ 
Suicide gene 
Prodrug Phase of 
study 
Sponsor Brief result ClinicalTrial.gov 
Identifier or PMID 
Liposome/ HSV-tk GCV I/II Max-Planck-
Institute of 
Neurological 
research 
Demonstrated 
safety 
PMID: 14520660 
Retrovirus/ HSV-tk GCV III Martin-Luther 
Universität 
No 
therapeutic 
benefit 
PMID: 11096443 
Adenovirus/  
HSV-tk 
GCV I University of 
Pennsylvania 
Not available NCT00002824 
Adenovirus/  
HSV-tk  
(aglatimagene 
besadenovec) 
Valacyclovir Ib Advantagene Safety 
demonstrated 
NCT00751270; 
PMID: 21844505; 
 
Adenovirus/  
HSV-tk  
(aglatimagene 
besadenovec) 
Valacyclovir IIa Advantagene Safe and 
favorable 
trend in 
survival 
benefit, 
ongoing 
NCT00589875; 
PMID:  26843484 
Retrovirus/ CD 
(Toca 511 or 
vocimagene 
amiretrorepvec) 
5-FC 
(Toca 5-FC) 
I Tocagen Well 
tolerated, 
statistically 
significant 
survival 
benefit 
NCT01156584; 
NCT01470794; 
NCT01985256 
PMID: 27252174 
Retrovirus/ CD 
(Toca 511 or 
vocimagene 
amiretrorepvec) 
5-FC 
(Toca 5-FC) 
II/III Tocagen Ongoing NCT02414165 
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Other approaches of viral vector mediated gene therapy for GBM 
Besides OV and SGT, other viral vector mediated cancer gene therapy 
approaches in general and GBM in particular involve the use of tumor suppressors, 
anti-angiogenic and immune stimulatory molecules 36.  
Tumor suppressor genes play important regulatory roles in cell proliferation, 
apoptosis and DNA repair. Mutations in these genes are common occurrences in 
different types of cancers including GBM. Mutations most commonly affecting 3 major 
pathways in GBM are regulated by tumor suppressor genes p53/MDM2, PTEN and 
p16/Rb37. Gene therapy strategies were designed to restore the normal function of 
these genes by delivering the wildtype versions to the tumor cells using viral vectors. 
This strategy showed tremendous promise in cell culture and small animal model 
studies leading to inhibition of tumor cell growth, induction of apoptosis and reduction 
in invasive properties38-43. It was also reported that tumor suppressor gene therapy 
could potentially re-sensitize tumor cells to other modes of therapies, such as radio- 
chemo- or immune-boosting gene therapy44-46. Recombinant adenovirus-mediated 
p53 gene therapy reached Phase I clinical trials (ClinicalTrials.gov Identifier: 
NCT00004041, NCT00004080) and showed minimal treatment-related toxicity, but the 
distribution of transduced cells was limited to ~ 5mm around the injection site. The 
major limitation of this approach is its complete dependence on direct and widespread 
gene transfer to tumor cells, which is usually very low, as the therapeutic mechanism 
involved lacks the benefit of any bystander effect. 
  New blood vessel formation (angiogenesis) is often associated with tumor 
growth and has been a popular target of different modalities of cancer treatment for 
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several years47-50. The proposed mechanism of antiangiogenic treatment involves 
inhibiting the angiogenic signaling pathways by silencing vascular endothelial growth 
factor (VEGF) or blocking VEGF receptors with the purpose of starving tumors of 
nutrients and oxygen. Several studies have reported that viral vector mediated 
antiangiogenic gene therapy provide therapeutic benefits in the animal models of 
GBM, especially when combined with other strategies like oncolytic treatments51,52. 
Different viral vectors such as HSV53,54, adenovirus55,56, adeno-associated virus57 and 
lentivirus58,59 have been implicated for treatment of GBM or other gliomas. The 
usefulness of this approach for GBM is now debated after disappointing results in late 
stage clinical trials (ClinicalTrials.gov Identifier: NCT00943826). Apparently anti-
angiogenic drug treatment only improved progression free survival (PFS), but there 
was no benefit in overall survival (OS) of GBM patients60. This suggests that the 
therapeutic benefit is only transitory and it hardly results in any long term tumor 
regression. Major challenges to anti-angiogenic gene therapy for GBM treatment with 
a single therapeutic molecule are the multitude of cellular feedback mechanisms, 
redundant signaling pathways and alternative receptors. Moreover, hypoxic conditions 
caused by antiangiogenic treatment have been shown to accelerate tumor growth and 
invasion and thus recurrence of tumor61-63.       
Another potential gene therapy approach is delivery of immune-stimulatory 
genes by viral vectors. Examples include adenoviral delivery of interferon-beta 
(IFN)64,65, parvoviral co-delivery of interferon-gamma (IFN)-inducible protein 10 
(IP10/CXCL10) and tumor necrosis factor-alpha (TNF)66, recombinant adeno-
associated virus (rAAV) and HSV mediated interleukin-12 delivery67-69. The approach 
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with local adenoviral delivery of IFN gene reached phase-I clinical trial 
(ClinicalTrials.gov Identifier: NCT00031083). The result showed no serious treatment-
related adverse effects except in one out of 11 patients treated70. One patient from the 
highest dose cohort showed grade IV confusion and local toxicity related to treatment. 
Nonetheless, the study demonstrated safety, feasibility and dose-dependent induction 
of tumor apoptosis and local inflammation at the injected site. While immune 
stimulatory gene therapy is a promising approach, dose and gene expression strength 
optimization, controlled stimulation of immune system, evading anti-viral immune 
response are some of the challenges for this approach.        
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Adeno-associated viral (AAV) vector as a gene delivery vehicle for GBM 
Adeno-associated virus is a replication-deficient DNA virus first discovered as a 
contaminant of adenovirus preparations71. AAV is a small (20nm diameter) non-
enveloped virus belonging to the Parvoviridae family and dependovirus genus since it 
requires other viruses (such as adenovirus or HSV) for its replication. The ~4.7kb 
linear single stranded DNA genome contains two open reading frames (ORFs) rep 
and cap. The rep ORF codes for four Rep proteins (Rep78, Rep68, Rep52 and 
Rep40) involved in viral DNA replication and packaging. The Rep78 and Rep68 
proteins are translated from the unspliced and spliced variants, respectively, of the 
same transcript that is transcribed from the p5 promoter. Similarly, Rep52 and Rep40 
are translated from the unspliced and spliced versions, respectively, of the same 
transcript that is transcribed from the p19 promoter. All four Rep proteins play 
important roles in different phases of AAV life cycle. For example, Rep78 and Rep68 
are involved in endonuclease activity that is required for nicking at the terminal 
resolution sites (TRS) after each round of DNA synthesis. They also play role in the 
site specific DNA binding at the Rep binding elements (RBE). The Rep52 and Re40 
have roles in viral DNA packaging within the AAV capsids. The cap ORF codes for 3 
capsid proteins (VP1, VP2 and VP3) that form the viral capsid and an assembly-
activating protein (AAP), which plays an important role in assembly and maturation of 
capsid. The VP1 (87kDa), VP2 (72kDa) and VP3 (62kDa) capsid proteins are 
translated from alternative splice variants of 2 different transcripts transcribed from the 
p40 promoter. VP1 is translated from the unspliced transcript and the other two cap 
proteins are produced from the spliced transcripts. Among these two, VP2 translation 
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takes place from the unconventional start codon ACG and VP3 is translated from 
conventional AUG codon (Figure II).  
AAV capsid structures are icosahedral in shape, each formed by 60 
capsomeres with a VP1: VP2: VP3 ratio of 1:1:10. These two ORFs are flanked by 
~145bp inverted terminal repeat (ITR) sequences necessary for DNA replication and 
packaging. The first 125bp of each ITR folds on itself to form T-shaped hairpin 
structure and the rest 20bp remains unpaired. ITRs serve as the replication origin as 
well as function as primers for second strand synthesis by DNA polymerase. ITRs also 
have crucial regions like RBE and TRS, which are crucial for viral DNA replication and 
processing of the double stranded intermediates72-75.   
The viral ITRs are the only cis-acting elements required for vector genome 
replication and packaging. The rest of the viral genome is replaced with the transgene 
cassette in the recombinant AAV vector (rAAV), thus minimizing the risk of 
immunogenicity to viral components. Despite the small DNA packaging capacity (only 
~4.7kb) rAAV is emerging to be one of the most attractive gene delivery vehicles for a 
number of reasons74,76. It is derived from a non-pathogenic non-replicating virus and 
thus much safer than other viral vectors. It can transduce both dividing and post-
mitotic cells widening the target cell spectrum. Moreover it is mostly retained in 
transduced cells as extrachromosomal DNA and thus poses a relatively low risk of 
insertional mutagenesis or oncogenesis. AAV vector is the least immunogenic among 
the viral vectors and provides sustained transgene expression in transduced cells over 
several years77, albeit it is also lost over time in dividing cell populations as it does not 
integrate in the genome. AAV vectors are also very stable78 and can be produced with  
xxxiii 
 
 
 
 
 
 
Figure II: Wildtype AAV viral genome with its products (left) and the AAV vector genome 
srtucture with transgene cassette (right). Rep78 and Rep68 are transcribed from the p5 promoter. 
Rep 78 is the unspliced product and Rep68 is the shorter spiced product. Rep52 and rep40 are 
transcribed from the p19 promoter. Rep 40 is the shorter spliced product of the two. The capsid proteins 
(VP1, VP2, VP3) and assembly-activating protein (AAP) are transcribed from the p40 promoter.  
Translations of VP2, VP3 and AAP are initiated from ACG, AUG and CUG initiation sites, respectively, 
present on the same transcript. The AAV vector is made by replacing the the viral genome with the 
transgene cassette comprising the promoter, transgen and polyA (pA). Inverted terminal repeats (ITRs) 
are the only cis element kept in the vector gene cassette (Adapted from Daya et al. 2008 and Sonntag 
et al. 2010, 2011)72,73,75.  
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high purity and titers with the current production methods79-83 and there are several 
natural as well as engineered capsid variants with diverse tissue tropism84. The 
favorable characteristics of AAV have made them the vector of choice for gene 
therapy interventions for central nervous system (CNS) diseases85.  
Unlike for other CNS diseases AAV has not been explored as extensively in 
cancer gene therapy, and only a small number have reached clinical trials 
(ClinicalTrial.gov identifier: NCT01637805, NCT02496273, NCT00590603). For GBM 
or high-grade gliomas there is no clinical trial currently running (according to 
ClinicalTrial.gov) that involves the use of an AAV vector. AAV mediated gene therapy 
studies for GBM in animal models are not that common either.  One possible reason 
could be that despite some attempts to engineer new AAV vectors with improved 
transduction efficiency for GBM cells86,87, the efficiency is still not satisfactory with the 
currently available AAV vectors. There could be several possible reasons why it is so 
difficult to transduce the GBM cells efficiently with AAVs. One such reason could be 
the inherent heterogeneity of GBM cells88-90. For example, several attempts with 
targeted molecular therapies against epidermal growth factor receptors (EGFRs) 
faced challenges in the clinics due to heterogeneity of GBM cells91-94. Similar 
challenges may also be true for GBM targeting with AAVs. Another possibility could be 
lack of sufficient AAV receptors and co-receptors on GBM cells, which may prevent 
binding or internalization of AAVs into tumor cell for effective transduction. Targeting 
GBM by the vascular route has additional challenges. Such as, abnormal vascular and 
blood brain barrier structure in the tumor may prevent tumor transduction by AAV 
upon delivery through vascular route. It is also possible that AAVs may get 
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sequestered from the blood by binding to some of the serum proteins or to some blood 
components before it reaches the tumor in the brain.  
Often the therapeutic strategy depends only on the direct transgene transfer to 
the tumor cells for its success. This approach is a self-limiting approach as once the 
transduced tumor cells are killed by the therapeutic effect, no more sources of 
therapeutic protein are then left to treat the untransduced tumor cells. Moreover, as 
AAV does not integrate with the host genome, AAV vector genomes get diluted in the 
rapidly diving GBM cells. Therefore a lot of GBM cells either escape AAV transduction 
or the therapeutic effect from it. Nonetheless, a few studies were carried out in the last 
decade with animal models of GBM that used AAV vectors (Table 3).  
 AAV gene therapy for GBM mostly employed therapeutic genes encoding 
secreted proteins, such as IFN95-98, soluble tumor necrosis factor-related apoptosis-
inducing ligand (sTRAIL)99,100 or soluble vascular endothelial growth factor receptor 
(sVEGFR1/R2)101,102 to benefit from the bystander effect and not solely depend on the 
direct tumor cell transduction efficiency. Possible therapeutic modes of action primarily 
involved inhibition of angiogenic signals95,101,102 and induction of apoptosis and 
necrosis99,100,103. While most of these studies provided prominent reduction in tumor 
and tumor vasculature growth rate, the success was usually transitory and survival 
prolongation largely remained moderate especially for the established orthotopic 
tumor models. One previous study from our group97 resulted in complete regression of 
an established orthotopic GBM and markedly improved survival. But, like most of the 
other studies, the GBM model used was non-invasive in nature. The only few 
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studies95,99,104 that used invasive primary human GBM showed minimal survival 
benefit after treatment with AAV gene therapy.  
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Table-III: AAV mediated GBM gene therapy studies  
in the last decade (2006-2016) 
(Source: Pubmed database) 
                                                  
Part -A 
Reference Harding et al.102 Streck et al.98 Nguyen et 
al.101 
Maguire et  
al.97 
Hingtgen et 
al.100 
 
AAV capsid AAV8 AAV8 N.A. AAVrh8 N.A. 
Therapeutic 
gene 
Soluble VEGF 
receptor 
(sVEGFR1/R2) 
IFN Rapamycin-
regulated 
soluble 
VEGF 
inhibitor 
IFN Secreted 
TRAIL 
Possible 
mode of 
action 
Antiangiogenic  Antiangiogenic Antiangiogeni
c (and mTOR 
inhibition) 
Pleotropic Induction of 
apoptosis 
and necrosis 
Delivery 
route 
Intravenous; 
intracranial 
Intravenous N.A. Intracranial Intracranial 
Animal and 
tumor model 
Athymic NCR-Nu 
mice 
(subcutaneous C6, 
4C8,U87); 
B6D2F1 mice 
(orthotopic 4C8); 
Athymic rat 
(orthotopic U-251) 
B6.CB17-
Prkdc<SCID>S
zJ 
(subcutaneous 
U87) 
N.A. Athymic 
nu/nu 
(orthotopic 
U87) 
Xenograft 
mouse 
model of 
Gli36-
EGFRvIII 
Brief results Reduces tumor 
volume and 
increases median 
survival 
Limited tumor 
and tumor 
vascular growth
Reduced 
tumor growth 
Eradicated 
tumor and 
increased 
survival 
Attenuation 
of tumor 
progression 
 
N.A.: Not Accessible information 
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Table-III: AAV mediated GBM gene therapy studies 
in the last decade (2006-2016) 
(Source: Pubmed database) 
 
 
Part-B 
 
 
 
 
  
 
  
Reference Meijer et al.96 
 
Dendo et al.95 Ma et al.103 
 
Hicks et al.104 
 
Crommentuijn 
et al.99  
AAV capsid AAVrh8 AAV5 AAV2 AAVrh.10 AAVrh.8 
Therapeutic 
gene 
IFN IFN decorin Bevacizumab 
(Avastin) 
Secreted 
soluble TRAIL 
Possible 
mode of 
action 
Pleotropic Antiangiogenic Induction of cell 
differentiation, 
apoptosis etc. 
Antiangiogenic Induction of 
apoptosis and 
necrosis 
Delivery 
route 
Intracerebrove
ntricular 
intracranial intracranial intracranial intracranial 
Animal and 
tumor model 
BALB/c nu/nu 
(Orthotopic 
U87) 
Nude rats 
(orthotopic 
MT330, GBM6 
and SJG2) 
Athymic nude 
mice 
(orthotopic 
U87)  
NOD/SCID 
mice 
(orthotopic U87 
and patient 
derived GBM) 
Mice 
(orthotopic 
U87, GBM8 
Brief results Pre-treatment 
completely 
prevents 
tumor growth; 
Survival 
improved for 
established 
tumor 
Tumor 
vasculature 
stabilized; 
slowed 
tumor(MT330) 
progression 
and improved 
survival; but did 
not affect tumor 
growth for 
GBM6 and 
SJG2 
Suppressed 
brain tumor 
growth, 
prolonged 
survival 
Reduced tumor 
and tumor 
vasculature 
density; 
prolonged 
survival 
Reduced 
tumor growth 
and prolonged 
survival (in 
combination 
with 
lanatoside C) 
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IFN gene therapy for GBM and rationale behind the current study  
            Interferons (IFNs) are glycoprotein cytokines that act as the first line of host 
defense system against invading pathogens105. The name ‘interferon’ came from its 
ability to ‘interfere’ with the pathogen infection106. IFNs are classified into three groups 
primarily based on the structure of their receptors. Type-I IFNs include IFN, IFN, 
IFN, IFN and IFN. The sole member of type-II IFN is IFN. Type III IFNs include 
different IFN molecules, viz., IFN1 (or IL-29) IFN2 (or IL-28A), IFN3 (or IL-
28B) and the recently discovered IFN4105,107.  
           Type-I IFNs are -helical cytokines that are secreted from almost all different 
types of nucleated cells upon viral or microbial infections. All type-I IFNs bind to a 
common heterodimeric receptor called IFN receptor or IFNAR. These receptors are 
expressed in almost all different kinds of cell types in the body. IFNARs are composed 
of two subunits - IFNAR1 and IFNAR2, which are associated with Tyrosine Kinase 2 
(TYK2) and Janus Kinase 1 (JAK1), respectively. Upon binding of type-I IFN to 
IFNAR, TYK2 and JAK1 are activated and they phosphorylate the cytoplasmic 
residues of IFNAR. These phosphorylated residues of IFNAR function as docking sites 
for signal transducers and activators (STATs). Once the STATs (STAT1, STAT2 or 
STAT3 are most commonly found STATs in different cell types) dock, they are 
phosphorylated by JAK1. These phosphorylated STATs form heterodimers or 
homodimers. Phosphorylated STAT1 and STAT2 heterodimer also recruits interferon 
regulatory factor 9 (IRF9) and forms IFN-stimulated gene factor-3 (ISGF3) complex. 
ISGF3 binds to IFN-stimulated response elements (ISREs) in the promoter regions of 
IFN-stimulated genes (ISGs) in the nucleus. This binding interaction modulates 
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transcription of these genes. On the other hand, STAT1 and STAT3 independently 
can form homodimers and these homodimers bind to gamma activated sequences 
(GAS). STAT1 homodimers induce pro-inflammatory gene expressions, whereas 
STAT3 homodimers indirectly inhibit pro-inflammatory gene expressions as they 
possibly induce some hitherto unknown repressors and they are associated with co-
repressor complex SIN3A105,108 (Figure III). 
Interferon beta (IFN) is a type-I IFN naturally secreted from cells upon viral 
infection, which activates ~300 genes in target cells through the JAK/STAT signaling 
pathway109. In addition to immunomodulation during viral infections, IFN is also 
reported to have anti-tumor properties that include direct cytostatic110 and pro-
apoptotic111 effects, as well as indirect effects such as anti-angiogenesis112,113, 
immune-stimulation114,115 and drug sensitization116. Several years ago it was also 
shown that in cell culture system recombinant IFN can significantly inhibit growth of 
human glioma cells117. More recently, a phase I study showed that using repeated 
intravenous delivery of recombinant IFN protein as an adjuvant to the standard-of-
care treatment could moderately improve the survival in patients without any severe 
side effects118. However the therapeutic success in this approach is limited due to the 
short half-life of IFN in blood119.  
Gene therapy can potentially overcome this limitation by genetically 
engineering cells in the target tissue to produce IFN protein locally. Moreover, as 
IFN is a secreted protein the therapeutic effect is expected to extend beyond the 
transduced cells.  
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Figure III: Type-I interferon signaling pathway. Binding of IFN or IFN to the IFN receptors 
activates the associated kinases (JAK1 and TYK2), which in turn induces docking and phosphorylation 
of STAT proteins. Phosphorylated STAT proteins form homodimers or heterodimers, which then 
translocate to the nucleus. There they bind to the ISRE or GAS sequences in the genome and induce 
different sets of genes (adapted from Ivashkiv et al. 2014)108. Abbreviations: Interferon (IFN); 
Interferon receptors (IFNAR); Janus kinase (JAK); Tyrosine kinase (TYK); Signal transducers and 
activator (STAT); IFN-stimulated response element (ISRE); Gamma activated sequences (GAS); SIN3 
transcription regulatory family member A (SIN3A).    
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Previously our group has shown that local intracranial delivery of a recombinant 
AAV vector encoding human IFN can eliminate orthotopic U87 human glioblastoma 
in an athymic nude mouse model97. This study demonstrated the principle that AAV 
mediated local IFN gene therapy could be useful for glioblastoma treatment. 
However, U87 tumor is non-invasive in nature, unlike glioblastoma in patients where 
infiltration and migration are important features of the tumors that contribute 
significantly to therapeutic failure. Therefore, in this study we first sought to test the 
intracranial AAVrh8-IFN based therapeutic approach in a highly invasive human 
glioblastoma model (GBM8)120 implanted in athymic nude mice (Chapter II). 
A limitation of therapeutic studies with human IFN in xenograft GBM models is 
that they have to be conducted in immuno-deficient athymic nude mice where human 
IFN does not interact with mouse IFN receptors121. The complex interaction of IFN 
with the immune system and tumor cells will determine the therapeutic outcome of an 
AAV-IFN strategy. Therefore, in a second set of experiments we tested the 
therapeutic efficacy of an AAV-IFN encoding the mouse cytokine in an orthotopic 
syngeneic mouse glioblastoma (GL261) model in normal C57BL/6J mice. Next, we 
compared the therapeutic efficacy of AAV-IFN combined with the standard-of-care 
chemotherapeutic drug TMZ treatment in relation to chemotherapy alone. Finally, we 
also tested the long term safety of this treatment modality in healthy C57BL/6J mice. 
A potential approach to counteract the properties of GBM cells that limits the 
efficacy of local interventions is to generate a disperse network of endogenous cells 
expressing IFN to prevent single tumor cell infiltration and growth, i.e. matching the 
delivery modality to the disease characteristics. Intravascular infusion of AAV9 vectors 
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achieves widespread gene delivery to the CNS of mice122 and large animals123,124. 
Therefore we hypothesized that systemic delivery of an AAV9-hIFN vector will be 
effective to generate a widely distributed CNS network to combat the invasive and 
migratory properties of GBM and treat distant multifocal GBM better compared to local 
gene delivery. In the Chapter-III we tested this concept in the orthotopic xenograft 
human GBM model (GBM8). 
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CHAPTER I: Materials and Methods 
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Cell culture:  
GBM8 cells were a kind gift from Dr. Samuel Rabkin (Massachusetts General 
Hospital, Boston, MA). These cells were transduced with the lentivirus vector CSCW2-
Fluc-IRES-mCherry as described97 to generate GBM8-Fluc cells constitutively 
expressing firefly luciferase. Cells were grown as neurospheres in neurobasal media 
(21103-049, Gibco, Grand Island, NY) supplemented with 3mM L-Glutamine (25-005-
CI, Mediatech Inc, Manassas, VA), 1x B27 supplement (17504-044, Gibco), 0.5x N2 
supplement (17502-048, Gibco), 2 g/ml heparin (H3400, Sigma-Aldrich, St. Louis, 
MO), 1x antibiotic-antimycotic solution (30-004-CI, Mediatech Inc) and 1x 
amphotericin B (30-003-CF, Mediatech Inc), 20 ng/ml recombinant human bFGF (100-
18B, PeproTech, Rocky Hill, NJ), and 20ng/ml of recombinant human EGF (AF-100-
15, PeproTech).  
GL261 cells were purchased from the Division of Cancer Treatment and 
Diagnosis, National Cancer Institute-Frederick, Bethesda, MD. The cells were grown 
in Dulbecco’s Modified Eagle Medium (11965-084, Gibco) supplemented with 10% 
Fetal Bovine Serum (F0926, Sigma-Aldrich), 1% Penicillin-Streptomycin (15140-122, 
Gibco) and 1% L-Glutamine (25-005-CI, Mediatech).  
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WST-1 assay: 
WST-1 assays (05015944001, Roche, Westborough, MA) were used to 
evaluate cell proliferation in the presence of recombinant human IFN (hIFN) protein 
or infection with AAV9/CB-mIFN for GBM8-Fluc or GL261 cells, respectively.  
Adherent GBM8-Fluc cells were cultured in plates pre-coated with laminin by overnight 
incubation with 10g/ml of laminin (23017015, Invitrogen) at 37oC. Studies were 
conducted in 12 well dishes seeded with 200,000 cells/well one day before initiating 
the studies. The following day the growth medium was replaced with fresh growth 
medium pre-mixed with 100 IU of recombinant hIFN protein (300-02BC, PeproTech) 
supplemented every 72 hours for GBM8 cells, or AAV9/CB-mIFN vector (at a dose of 
100,000 vg/cell) for GL261 cells.  
Animals: 
Six to eight week-old male athymic nude mice were obtained from the NCI 
(Bethesda, MD) for this study. For the syngeneic tumor study, 6-8 weeks old male 
C57BL/6J mice were used (Jackson Laboratory, Bar Harbor, ME). All animal studies 
were approved by the UMass Medical School Institutional Animal Care and Use 
Committee following guidelines set forth by the NIH Guide for the Care and Use of 
Laboratory Animals.   
Tumor cell grafting in mouse brain: 
Two days prior to implantation in mouse, the media of GBM8-Fluc cells was 
replaced with fresh media. On the day of injection GBM8-Fluc cells were dissociated 
into a single cell suspension by pipetting. Cells were washed twice in Dulbecco’s 
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phosphate-buffered saline (14190-250, Gibco) and resuspended in the same to a 
concentration of 50,000 cells/µl. One µl of cell suspension was injected stereotaxically 
into the left striatum. The studies in the syngeneic mouse model were carried out in 
C57BL/6J mice implanted with 10,000 GL261 cells using the same injection 
parameters. The stereotaxic coordinates for tumor implantation from bregma were (in 
mm): AP: +0.5, ML: 2.0 (left) and DV from brain surface: -2.5. Bilateral tumors were 
generated by injecting 50,000 GBM8-Fluc cells into both striata.  
AAV vector design, production and delivery: 
For the intracranial xenograft study, AAVrh8/CBA-hIFN and a corresponding 
AAVrh8 vector without a transgene (empty vector) were used, as previously 
described97. For the studies in the syngeneic mouse tumor model the following vectors 
were used: AAV9/CB-mIFN, AAV9/P2-Int-mIFN, AAV9/hSyn1-mIFN, AAV9/Ple32-
mIFN and AAV9/Ple88-mIFN. These vectors contained mouse IFN cDNA under 
the control of CB, P2-Int, human Syn1, Ple32 and Ple88 promoters, respectively, and 
were packaged inside AAV9 capsids. Detail descriptions of the promoters are 
provided in Table 1.1. For the GFP reporter study, the vectors used were: AAV9/P2-
Int-EGFP and AAV9/Ple88-EGFP encoding the enhanced green fluorescence (EGFP) 
protein. 
All recombinant AAV9s used in the systemic delivery study were self-
complementary (sc) vectors. The vectors scAAV9/CB-hIFN and scAAV9/CB-hIFN-
miRBS-1-122 encode human interferon- under the chicken -actin promoter and 
cytomegalovirus enhancer (CB promoter) and carry a rabbit beta-globin 
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polyadenylation (RBGpA) signal. The scAAV9/CB-hIFN-miRBS-1-122 vector carries 
3 copies of miR-1 and miR-122 binding sites (miRBS) in the 3’untranslated region as 
described125. scAAV9/TBG-hIFN vector carries a thyroxin binding globulin (TBG) 
promoter to drive liver-specific gene expression126. The scAAV9/CB-EGFP and 
scAAV9/TBG-EGFP vectors encode enhanced green fluorescence protein (EGFP).  
AAV vectors were produced at the Horae Gene Therapy Center Viral Vector 
Core at UMass Medical School as described127. Vector titers were determined by 
quantitative PCR (qPCR) of vector genomes using the following primers and probe 
specific for RBGpA (Eurofins, Luxembourg City, Luxembourg):  
Primer1:5’-GCCAAAAATTATGGGGACAT-3’;  
Primer2: 5’ATTCCAACACACTATTGCAATG-3’;   
Probe: 6FAM-ATGAAGCCCCTTGAGCATCTGACTTCT-TAMRA 
For systemic administration AAV9 vectors were injected via the tail vein in a 
total volume of 200 µl. In the intracranial treatment paradigm 7.6x109 genome copies 
(gc) of scAAV9/CB-hIFN vector was infused in 2 µl at 200 nl/min in the same 
stereotaxic coordinates used for tumor implantation. 
Temozolomide treatment: 
 Temozolomide (S1237, Selleckchem, Houston, TX) powder was reconstituted 
in dimethyl sulfoxide (DMSO) (BP-231-100, Thermo Fisher Scientific, Fair Lawn, NJ) 
at a concentration of 20mg/ml and stored frozen at -80oC as single-use aliquots. 
Working solution was prepared immediately prior to injection by diluting 
temozolomide/DMSO stock solution in sterile PBS to a final concentration of 5mg/ml. 
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The solution was then cooled down to room temperature and injected intraperitoneally 
at a dose of 2.5mg/mouse daily for 5 consecutive days from day-4 to day-8 (regimen-
1) or day-10 to day-14 (regimen-2) after GL261 tumor implantation in C57BL/6J mice.  
Live bioluminescence imaging: 
Imaging of tumor associated bioluminescence signal (TABS) was performed 
using a Xenogen IVIS 100 imaging system (PerkinElmer, Hopkinton, MA) 3 minutes 
after intraperitoneal administration of D-luciferin (4.5 mg). Image analysis was 
performed using Living Image software (PerkinElmer). 
 
Preparation of tissue DNA and RNA and quantification of vector genomes and 
IFNβ transcripts:  
Total DNA was extracted using DNeasy Blood & Tissue kit (QIAGEN, Hilden, 
Germany). DNA was diluted to a final concentration of 50-100ng/l for vector genome 
quantification by qPCR using RBGpolyA specific primers and probe. 
Tissue RNA was isolated from nude mouse organs or from 3mm striatal 
punches from injected sites in the C57BL6/J mice using TRIzol (15596-018, 
Invitrogen, Carlsbad, CA) and Direct-zol RNA MiniPrep (R2052, Zymo Research 
Corporation, Irvine, CA). RNA was treated with TURBO DNase (AM1907, Ambion, 
Foster City, CA) for 30 minutes at 37oC prior to reverse transcription using High 
Capacity RNA-to-cDNA kit (4387406, Applied Biosystems, Foster City, CA). 
Quantitative PCR was performed with the following primers and probe for hIFN (IDT, 
Coralville, IA):   
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Primer-1: 5’-GCAATTGAATGGGAGGCTTG-3’;  
Primer-2: 5’-TCATAGATGGTCAATGCGGC-3’;  
hIFN Probe: 5’-/6FAM/TGTCAAAGT/ZEN/TCATCCTGTCCTTGAGGC/3IABkFQ.  
The following primers (IDT) and probe (TIB Molbiol) were used for qPCR 
quantification of bovine growth hormone polyadenylation signal (BGHpA) present on 
AAV transgene transcripts for the syngeneic study in C57BL6/J mice.  
Forward primer:  5’-CCTCGACTGTGCCTTCTAG-3’;  
Reverse primer: 5’-TGCGATGCAATTTCCTCAT-3’;  
BGHpA probe: 6FAM-TGCCAGCCATCTGTTGTTTGCC-BBQ.  
The qPCR amplifications were performed using Taqman gene Expression 
Master Mix (4369016, Applied Biosystems). Mouse HPRT1 expression was used as 
an internal reference gene to normalize all values (Assay ID: Mm00446968_m1; 
Applied Biosystems). Mean expression values for PBS group animals were 
considered to be background noise and thus subtracted from all values. 
Quantification of human IFN in cell conditioned media and mouse plasma: 
hIFN in conditioned growth media and mouse plasma was measured using 
ELISA assays (41410 and 41415, PBL Assay Science). Conditioned growth media 
was collected for ELISA 48 hours after transfection. Mouse plasma was collected 1 
month after AAV infusion. Media and plasma were diluted 1:10 and 1:4,000 in PBS, 
respectively for ELISA measurements.  
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Mouse IFN protein extraction from brain and detection by Western Blot: 
Mouse brain punches (3mm diameter) were taken from the injection sites 1 
month post AAV9/mIFN injections. The tissues were cut into small pieces and frozen 
immediately on dry ice/2-methyl butane bath and stored at -80oC freezer. At a later 
point, protein for Western Blot was extracted from the frozen tissue pieces using bead 
lysis at 20Hz for 2 minutes in round bottom 2 ml centrifuge tubes in T-Per tissue lysis 
buffer (78510, Thermo Fisher Scientific) supplemented with Complete Mini Protease 
Inhibitor cocktail  (11836153001, Roche). Tissue lysates were spun down at 12,000xg 
for 1 min at 4oC and protein was measured from the supernatant using Bradford 
protein assay (5000201, Bio-Rad). Total protein (60g per sample) was run to 
separate in polyacrylamide gel electrophoresis in 4-20% Mini-PROTEAN TGX gels 
(4561094, Bio-Rad) and transferred to nitrocellulose membrane. Primary antibodies 
used in western blots: Rabbit polyclonal anti-mouse IFN antibody (AB2215, EMD 
Millipore, dilution 1:250) and mouse monoclonal anti--actin antibody (A5441, Sigma-
Aldrich, dilution 1:1000). Secondary antibodies: Horse radish peroxidase (HRP)-
conjugated ECL donkey anti-rabbit IgG (NA934V, GE Healthcare, Westborough, MA, 
dilution 1:10,000) and HRP-conjugated ECL sheep anti-mouse IgG (NA931V, GE 
Healthcare, dilution 1:10,000). Pierce ECL Western Blotting Substrate (32106, Thermo 
Fisher Scientific) was used for detection and X-ray films were exposed for 30 min and 
30 sec for mIFN and -actin detection, respectively.  Two independent protein 
preparations were used for each sample.    
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Histological analysis: 
Brain cryosections (20 µm) and paraffin section (5 µm) were used for 
histological studies. Mayer’s Hematoxylin (MHS16, Sigma-Aldrich) and Eosin Y 
alcoholic solution with phloxine (HT110316, Sigma-Aldrich) were used for histological 
staining. The primary antibodies used for immunohistochemistry or 
immunofluorescence stainings were: rabbit monoclonal anti-GFP (G10362, Invitrogen, 
dilution 1:1000), rabbit polyclonal anti-Iba1 (019-19741, Wako, dilution 1:500), rabbit 
polyclonal anti-CD3 (ab5690, Abcam, dilution 1:100), rabbit monoclonal anti-Olig2 
(ab109186, Abcam, dilution 1:250) and mouse anti-human nuclei (1:150, MAB4383, 
EMD Millipore, Billerica, MA). Biotinylated goat anti-rabbit IgG (BA-1000, Vector 
Laboratories, dilution 1:1000),  Alexa-fluor 488 conjugate F(ab’)2-goat anti-rabbit IgG 
(A-11070, Thermo Fisher Scientific, dilution 1:1000) and Alexa-fluor 594 goat anti-
mouse (A-11020, Thermo Fisher Scientific, dilution 1:2000) were used as secondary 
antibodies. Sections were counterstained with nuclear stains 4’,6-diamidino-2-
phenylindole (DAPI) (PI-62247, Thermo Fisher Scientific, 0.1g/ml) for 
immunofluorescence staining and with Mayer’s hematoxylin (Sigma) for 
immunohistochemical detections. VECTASTAIN Elite ABC Kit (PK-6100, Vector 
Laboratories) and DAB substrate kit (SK-4100, Vector Laboratories) were used for 
immunohistochemical staining. Luxol Fast Blue staining for the 5 paraffin brain 
sections were carried out using standard protocol by Morphology Core at University of 
Massachusetts Medical School. Three or four different brains and 3 individual sections 
from each brain were analyzed for all histological data and the images shown are 
representative. Leica DM5500 B microscope (Leica Microsystems) was used for all 
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image acquisitions and Adobe Photoshop CS6 (Adobe Systems) was used for image 
processing.    
Graphs and Statistical analysis: 
Kaplan-Meier survival curves were plotted in Prism 6 (GraphPad Software), and 
the Mantel-Cox log-rank test was used for statistical analysis. Bar graphs were also 
plotted using the same software and an unpaired 2-tailed t test was used for statistical 
analysis. Calculated P values were defined as the probability of null hypothesis being 
true; *P<0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001; ns, not significant (P>.05). 
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Table 1.1: Promoter descriptions: 
 
 
 
 
 
Promoter name CBA 
Description Chicken beta actin promoter with cytomegalovirus immediate early (CMV IE) 
enhancer, beta-actin exon and a chimeric intron 
Sequence CGCGTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGG
TCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGT
AAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTC
AATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC
GTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCA
AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAAT
GGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC
TTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTCGAGGTGA
GCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCC
AATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGG
GGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGG
GCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGC
GGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCG
GCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGACGC
TGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCC
CCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACG
GCCCTTCTCCTCCGGGCTGTAATTAGCGCTTGGTTTAATGACGGCTTGT
TTCTTTTCTGTGGCTGCGTGAAAGCCTTGAGGGGCTCCGGGAGCTAGAG
CCTCTGCTAACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGC
AACGTGCTGGTTATTGTGCTGTCTCATCATTTTGGCAAAGAATTCCTCGA
AGATCCGAAGGGGTTCA 
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Table 1.1 (continued) 
 
 
 
 
 
Promoter name CB 
Description Chicken beta actin with CMV IE enhancer, but no introns 
Sequence CGCGTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGG
TCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGT
AAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTC
AATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC
GTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCA
AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAAT
GGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC
TTGGCAGTACATCTACGTATTAGTCATCGCTATTACCCACGTTCTGCTTC
ACTCTCCCCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATT
TTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGCGCGCGC
CAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGA
GAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTT
TTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCG
CGGCGGG 
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Table 1.1 (continued) 
 
Promoter name Ple88 
Description Originally derived from human Glial fibrillary acidic protein promoter, sourced 
from Addgene plasmid #29176: pEMS1375, described in Portales-Casamar 
et al., PNAS, 2010 (PMID: 20807748). 
Sequence GGCCGGCCCAGATGTGACTAGAGCCTAAGGAGCTCCCACCTCCCTCTC
TGTGCTGGGACTCACAGAGGGAGACCTCAGGAGGCAGTCTGTCCATCA
CATGTCCAAATGCAGAGCATACCCTGGGCTGGGCGCAGTGGCGCACAA
CTGTAATTCCAGCACTTTGGGAGGCTGATGTGGAAGGATCACTTGAGCC
CAGAAGTTCTAGACCAGCCTGGGCAACATGGCAAGACCCTATCTCTACA
AAAAAAGTTAAAAAATCAGCCACGTGTGGTGACACACACCTGTAGTCCC
AGCTATTCAGGAGGCTGAGGTGAGGGGATCACTTAAGGCTGGGAGGTT
GAGGCTGCAGTGAGTCGTGGTTGCGCCACTGCACTCCAGCCTGGGCAA
CAGTGAGACCCTGTCTCAAAAGACAAAAAAAAAAAAAAAAGAACATATCC
TGGTGTGGAGTAGGGGACGCTGCTCTGACAGAGGCTCGGGGGCCTGA
GCTGGCTCTGTGAGCTGGGGAGGAGGCAGACAGCCAGGCCTTGTCTGC
AAGCAGACCTGGCAGCATTGGGCTGGCCGCCCCCCAGGGCCTCCTCTT
CATGCCCAGTGAATGACTCACCTTGGCACAGACACAATGTTCGGGGTGG
GCACAGTGCCTGCTTCCCGCCGCACCCCAGCCCCCCTCAAATGCCTTC
CGAGAAGCCCATTGAGCAGGGGGCTTGCATTGCACCCCAGCCTGACAG
CCTGGCATCTTGGGATAAAAGCAGCACAGCCCCCTAGGGGCTGCCCTT
GCTGTGTGGCGCCACCGGCGGTGGAGAACAAGGCTCTATTCAGCCTGT
GCCCAGGAAAGGGGATCAGGGGATGCCCAGGCATGGACAGTGGGTGG
CAGGGGGGGAGAGGAGGGCTGTCTGCTTCCCAGAAGTCCAAGGACACA
AATGGGTGAGGGGACTGGGCAGGGTTCTGACCCTGTGGGACCAGAGTG
GAGGGCGTAGATGGACCTGAAGTCTCCAGGGACAACAGGGCCCAGGTC
TCAGGCTCCTAGTTGGGCCCAGTGGCTCCAGCGTTTCCAAACCCATCCA
TCCCCAGAGGTTCTTCCCATCTCTCCAGGCTGATGTGTGGGAACTCGAG
GAAATAAATCTCCAGTGGGAGACGGAGGGGTGGCCAGGGAAACGGGG
CGCTGCAGGAATAAAGACGAGCCAGCACAGCCAGCTCATGTGTAACGG
CTTTGTGGAGCTGTCAAGGCCTGGTCTCTGGGAGAGAAGCACAGGGAG
GCCAGACAAGGAAGGGGTGACCTGGAGGGACAGATCCAGGGGCTAAA
GTCCTGATAAGGCAAGAGAGTGCCGGCCCCCTCTTGCCCTATCAGGAC
CTCCACTGCCACATAGAGGCCATGATTGACCCTTAGACAAAGGGCTGGT
GTCCAATCCCAGCCCCCAGCCCCAGAACTCCAGGGAATGAATGGGCAG
AGAGCAGGAATGTGGGACATCTGTGTTCAAGGGAAGGACTCCAGGAGT
CTGCTGGGAATGAGGCCTAGTAGGAAATGAGGTGGCCCTTGAGGGTAC
AGAACAGGTTCATTCTTCGCCAAATTCCCAGCACCTTGCAGGCACTTACA
GCTGAGTGAGATAATGCCTGGGTTATGAAATCAAAAAGTTGGAAAGCAG
GTCAGAGGTCATCTGGTACAGCCCTTCCTTCCCTTTTTTTTTTTTGTGAG
ACAAGGTCTCTCTCTGTTGCCCAGGCTGGAGTGGCGCAAACACAGCTCA
CTGCAGCCTCAACCTACTGGGCTCAAGCAATCCTCCAGCCTCAGCCTCC
CAAAGTGCTGGGATTACAAGCATGAGCCACCCCACTCAGCCCTTTCCTT
CCTTTTTAATTGATGCATAATAATTGTAAGTATTCATCATGGTCCAACCAA
CCCTTTCTTGACCCACCTTCCTAGAGAGAGGGTCCTCTTGCTTCAGCGG
TCAGGGCCCCAGACCCATGGTCTGGCTCCAGGTACCACCTGCCTCATG
CAGGAGTTGGCGTGCCCAGGAAGCTCTGCCTCTGGGCACAGTGACCTC
AGTGGGGTGAGGGGAGCTCTCCCCATAGCTGGGCTGCGGCCCAACCC
CACCCCCTCAGGCTATGCCAGGGGGTGTTGCCAGGGGCACCCGGGCAT
CGCCAGTCTAGCCCACTCCTTCATAAAGCCCTCGCATCCCAGGAGCGAG
CAGAGCCAGAGCAGGTTGGAGAGGAGACGCATCACCTCCGCTGCTCGC
GGCGCGCC 
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Table 1.1 (continued) 
 
  
 
 
 
 
 
 
Promoter name Ple32 
Description Originally derived from human Claudin 5 promoter, sourced from Addgene 
plasmid #29299: pEMS1503, described in Portales-Casamar et al., PNAS, 
2010 (PMID: 20807748) and de Leeuw et al., MTM, 2014 (PMID: 24761428). 
Sequence CTTGCCTTCAGAACCTCCCCACACTAGGTGAGCCAGACGCTGGCCTTAT
CTCATTTACCATCTCAGAGCCATCTGAAGGGGGAGAAGGGAACCGGGC
CCCAGGAGGGAGAAAGTCATCAAACCTCCCACATCTGTGACCAGCCTCA
GTGCCATACTTTTTCTATGGAGGGCCCTGTCCAATGGAACTGAGCACAG
ACCAGATAAAAGAACTGGGCACCCAGTGGCCTCAGTCCAGGGCCTGGA
GTTCAAACTTTACTGGAAACAAAGGGGCCGAGAGAGACTGGGGAAAGAA
CTACTAGAAAGGGGCTGGTGCCCCCATGGGGCTGTGGGTTTTGGAGCC
GCGTGCCCCCACCTGAGCCTCAGGGGGCCCGGAGTGTCCACACCAGT
GGACCTTTCGAGAAATGGCTGGGCCATTGTGCAGAAGAATGCCCGGAA
ATCCCGCGCCTCCCTCCTCCAGCAAGGATGGGGGCTCTTCCTCCTGGC
CAGGAAACTCCAAGTTGGCTTCCGGAGGGTGGCCTGGGGGCTGGGGT
GCCAGGGACACCATCGCCACTGGTGGGAGGGCAGGGCACAGCCCCTC
CGTGTCCCTTTGTCTCTCCTGTCTGAAGGCCAGAGCAGGCTGCTAGGCC
TGGGGCCACCACTGCCCCTGGGTGCTACACCCAGTGTGCTGGGTCACT
GGGAACTTCCTGAAGTGGTGTCACCTGAACTGGGCCCCCAAGGATGGG
GTGCGGGCAGTACCGCAGGAAGAGGAGCAGCCCCTGTGAAGATTGAGA
GGTCTGGGAAGCCCCTGCGGCTTGGGAGAGTGGGGGTCGCCAGGCAG
GGGGAAAGCCCCTGTGCCACCGCTTTTTGCCAGAGACTCAGGCTCCAG
AGAGGCAGTGAGTGGCATGGGGGGTGAGGCTGGGGCCCTGGGCCTGA
CCTCCACACGCCTGCCTGGCCTCTCTGTTTGCCATGGGATGAGAGAGAC
AGTGCTGGGACTCAGAGCGGGGCTGGAGAGTGAGAGTGCGAGAAAGG
GCCTGGGTGGGGCTTGGACCCCGGGGCGGGCTTTCTGGAGAGCCCCC
CTACGAGGGCCTCTACGGCGGTGACGGGGTGGGGGGCTTCTGCAAAC
CTTGGTCAGGGAAGTGGAGCTGGCTCGAGTGGAAGAGACCACCCGGCT
CAGTCGGGGATGTGGGAGTGGACTGGGTGGTGCAGACTGGGGGTCGA
GCGCCTTCTGAAGTGACGGGGCCGGGACGCGCAGGGAGGCGGCCCAA
GAAGCGCGCCCTAGGCCAGCCCAGAATGCGCTCGGCCGCGACTAGGA
CAACGGCGGGTGGGGCTGGGGGCGGCTGCCGGGCGGGGAGCGGTCC
CGCGCCCTCAGCTACCCCTCAAGAGCCGTTGTTTCCCTAACTTCAGCTG
CCAGAGGCTCTGTGATTGGCTGCGGCACGATGACCCGCGCACGGATTG
GCTGCTTCGGGCCGGGGGGCCGGGCCCGGGGGACAGAATCCGCCCCC
GAACCTTCAAAGAGGGTACCCCCCGGCAGGAGCTGGCAGACCCAGGAG
GTGCGACAGACCCGCGGGGCAAACGGACTGGGGCCAAGAGCCGGGAG
CGCGGGCGCAAAGGCACCAGGGCCCGCCCAGGGCGCCGCGCAGCAC
GGCCTTGGGGGTTCTGCGGGCCTTCGGGTGCGCGTCTCGCCTCTAGCC 
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Table 1.1 (continued) 
 
 
 
 
 
 
 
 
  
Promoter name hSyn1 
Description Human Synapsin1 promoter 
Sequence GAGGGCCCTGCGTATGAGTGCAAGTGGGTTTTAGGACCAGGATGAGGC
GGGGTGGGGGTGCCTACCTGACGACCGACCCCGACCCACTGGACAAG
CACCCAACCCCCATTCCCCAAATTGCGCATCCCCTATCAGAGAGGGGGA
GGGGAAACAGGATGCGGCGAGGCGCGTGCGCACTGCCAGCTTCAGCA
CCGCGGACAGTGCCTTCGCCCCCGCCTGGCGGCGCGCGCCACCGCCG
CCTCAGCACTGAAGGCGCGCTGACGTCACTCGCCGGTCCCCCGCAAAC
TCCCCTTCCCGGCCACCTTGGTCGCGTCCGCGCCGCCGCCGGCCCAG
CCGGACCGCACCACGCGAGGCGCGAGATAGGGGGGCACGGGCGCGA
CCATCTGCGCTGCGGCGCCGGCGACTCAGCGCTGCCTCAGTCTGCGGT
GGGCAGCGGAGGAGTCGTGTCGTGCCTGAGAGCGCAGTCGAGA 
Promoter name P2-Int 
Description Transcriptional element 7 (ATF-1/CRE/Sp1/C+TATA Box) as described in US 
Patent No. 6,346,415 B1, dated Feb. 12, 2002. The chimeric intron from CBA 
promoter was added downstream to this promoter. 
Sequence CTGGAGCCGGTGTCAGGTTGCTCCGGTAACGGTGACGTGCACGCGTGG
GCGGAGCCATCACGCAGGTTGCTATATAAGCAGAGCTCGTTTAGTGAAC
CGTCAGAGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCG
CCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCC
CACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGC
GCTTGGTTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGTGAAAGCCTT
GAGGGGCTCCGGGAGCTAGAGCCTCTGCTAACCATGTTCATGCCTTCTT
CTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGTCTCATC
ATTTTGGCAAAGAATTCC 
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CHAPTER II: Local gene therapy for glioblastoma  
with intracranial delivery of AAV-IFN
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Abstract: 
Here we have tested the efficacy of local AAV-IFN gene therapy in two 
different glioblastoma (GBM) models. First, we show here that single local injection of 
AAV-IFN can completely eliminate highly invasive human glioblastoma from 
xenograft nude mouse model and provide long term survival. Next, we show that in a 
normal immunocompetent mouse model (C57BL/6J) this treatment approach can 
effectively cause extensive cell death in the tumor center and provide moderate 
improvement in survival. Combination of standard chemotherapeutic drug 
temozolomide with AAV-IFN treatment further improves the survival benefit over any 
single mode of treatment and more than doubles the median survival when compared 
to PBS control group. Using immunohistological staining we looked at the presence 
and morphology of some of the important immune cells in the tumor bearing brains 
before and after AAV-IFN treatment which could possibly have serious implications in 
the observed therapeutic outcome. Finally, we have performed a long term safety 
study for intracranial treatment with AAV-IFN vectors in healthy C57BL/6J mice. We 
report that long term continuous expressions of species-matched IFN show 
noticeable demyelinating neurotoxic effect in the brains and body weight loss in some 
groups.  
18 
 
 
Results: 
Single intracranial injection of AAV-hIFN successfully treats tumors in invasive 
glioblastoma xenograft model. 
  Treatment of GBM8-Fluc cells in culture with recombinant human IFN over a 
9-day period resulted in significant inhibition of proliferation by day 6 (Figure 2.1A). 
Next, we tested the therapeutic efficacy of intracranial administration of 3x1010 gc 
AAVrh8-hIFN in GBM8 tumor bearing mice at 2, 3 or 4 weeks after tumor 
implantation (Figure 2.1B). Tumor growth was assessed weekly by live imaging of 
tumor-associated bioluminescence signal (TABS) starting at five weeks after tumor 
implantation, a time when there was no detectable TABS in week-2 treatment group 
animals, whereas, all animals in the empty vector control group showed high signals. 
In week-3 and week-4 treatment groups there was considerable variability in TABS 
among animals (Figure 2.1C). An 8-month study showed that 83.3% of mice in the 
week-2 group survived until the experimental endpoint, whereas all animals in control 
groups (untreated and empty vector) were euthanized on or before day-50 after tumor 
implantation with median survivals of 47-49 days. Consistent with the variability in 
TABS, a smaller percentage of animals in week-3 (33.3%) and week-4 (40%) groups 
survived until the experimental endpoint with median survivals of 66 days and 110 
days, respectively (Figure 2.1D). Histological analysis of brains at the endpoint 
revealed diffuse ipsilateral tumors and long-distance migration to the contralateral 
hemisphere in animals from control groups. In contrast, there was no evidence of 
tumors in animals that survived to the experimental endpoint at 8 months. In animals 
from week-3 and week-4 treatment groups that reached the humane endpoint showed  
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Figure 2.1: Local intracranial injection of AAVrh8/CBA-hIFN improves survival of GBM8-Fluc 
implanted athymic nude mice. (A) WST-1 assay shows effect of recombinant hIFN protein treatment 
on GBM8-Fluc cell proliferation in culture. GBM8-Fluc cells were treated with 100 IU recombinant hIFN 
every 72 hours. Student’s unpaired t test results: *p < 0.05; **p<0.01. (B) Schematic diagram showing 
timing of tumor implantation, AAVrh8/CBA-hIFN treatment and bioluminescence imaging (C) 
Representative images of tumor-associated bioluminescence signal in live mice from different groups. 
Two randomly chosen animals from each treatment group are shown. (D) Kaplan-Meier survival curves 
for treatment at different time-points after tumor implantation: week-2 (red curve), week-3 (green curve) 
and week-4 (blue curve). Empty vector control (black curve) was injected at week-2. Another control 
group was left untreated (orange curve). Number of animals per group (n) = 5 for untreated and week-3 
treatment groups. For all other groups, n=6. Log-rank test (compared to empty vector group): *p < 0.05; 
***p<0.001. (E) Representative rostral-caudal brain sections at the experimental endpoint for week-2 
treatment (day 244), and humane endpoints for empty vector (day 44) and week-4 treatment (day 65). 
Abbreviations: wk, weeks post tumor implantation; d, days post tumor implantation. 
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tumors of varying sizes and spread. Of note is that in several animals large tumors 
were found in the contralateral hemisphere and these appeared less diffuse than 
tumors in control groups (Figure 2.1E).    
   
Single intracranial injection of AAV-mIFN improves survival of normal mice 
with syngeneic GL261 brain tumors 
 Next we tested the therapeutic efficacy of intracranial AAV-IFN gene therapy 
in the GL261 brain tumor model in C57BL/6J mice. For these studies all AAV vectors 
encoded mouse IFN (mIFN) as the human cytokine does not have anti-proliferative 
properties in mouse tumors121. Transduction of GL261 cells in culture with AAV9-
mIFN resulted in significant inhibition of proliferation by day 6 compared to both PBS 
and AAV9-EGFP controls (Figure 2.2A).  
As IFN is a potent cytokine we tested five different AAV9 vectors encoding 
mIFN under different promoters (Table 1.1) for safety and anti-tumor effect in a pre-
treatment experimental model. AAV9 vectors (5x109 gc) were injected in the striatum 
two weeks prior to injection of GL261 tumor cells in the same stereotaxic co-ordinates 
and the effect on survival analyzed. Kaplan-Meier survival curves (Figure 2.3) showed 
that groups treated with AAV9 vectors carrying Ple32 and CB promoters had lower 
median survival (21 days) than the PBS control group (25 days), suggestive of toxicity. 
Hence, these two vectors were excluded from further therapeutic studies. The other 3 
groups treated with AAV9 vectors carrying promoters P2-Int, hSyn1 and Ple88 
showed 
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Figure 2.2:  Local intracranial injection of AAV9-mIFN improves survival of GL261 tumor 
bearing mice. (A) WST-1 assay shows effect of AAV9/CB-mIFN treatment (MOI=105) on GL261 cell 
proliferation in culture. Controls were treatment with AAV9/CB-EGFP vector or PBS. Unpaired 
Student’s t test results: ***p<0.001. (B) Experimental design (top) and Kaplan-Meier survival curves 
(bottom) for therapeutic efficacy study in GL261 implanted C57BL/6J mice treated with three different 
AAV9 vectors expressing mIFN under different promoters: P2-Int (red curve), hSyn1 (blue curve) and 
Ple88 (green curve). PBS was injected as control (black curve). Number of animals per group (n) =5. 
Log-rank test results, *p<0.05, **p<0.01. (C) Representative pictures of tumors at the humane 
endpoints from different vector treatment groups and PBS control. Asterisks indicate the site of 
extensive cells death after treatment. Scale bar represents 500m.  
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Figure 2.3: Survival assay of GL261 tumor bearing mice after pre-treatment with AAV9-mIFN.  
Experimental paradigm (top) and Kaplan-Meier survival curve (bottom) for GL261 implanted C57BL/6J 
mice pre-treated with AAV9 vectors encoding mIFN under different promoters (P2-Int, hSyn1, CB, 
Ple32, Ple88) or PBS.   
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small improvements in median survival to 31, 31 and 33 days, respectively (Figure 
2.3). These three vectors were selected for further studies.   
Tumor bearing mice received intra-striatal injections of the AAV9-mIFN 
vectors selected above (3x1010 gc), or PBS, at the site of GL261 tumor cell 
implantation. Kaplan-Meier survival curves showed moderate but statistically 
significant improvements in survival for all AAV treatment groups. Median survivals 
were improved to 31, 32 and 39 days for Ple88, hSyn1 and P2-Int groups, 
respectively, from 25 days in PBS control (Figure 2.2B). Histological analysis revealed 
extensive cell death in the tumor center in AAV treatment groups unlike the more 
uniform appearance of tumors in the PBS control group (Figure 2.2C).  
 
Transgenes are expressed in brain after AAV9 gene delivery to mouse striatum.  
 The therapeutic effect of AAV9-mIFN vectors was likely mediated by 
expression of IFN as its mRNA (Figure 2.4A) and protein (Figure 2.4B) levels were 
elevated in the injected striatum compared to PBS controls. The hSyn1 promoter is 
known to drive neuron-specific transgene expression in mouse brain after AAV 
mediated delivery128. Striatal injection of AAV9/P2-Int-EGFP and AAV9/Ple88-EGFP 
vectors (3x1010 gc) resulted in efficient distribution and transduction of cells of 
primarily neuronal phenotype (Figure 2.4C, 2.5).  
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Figure 2.4: Transgene expression in brain after AAV9 mediated intracranial delivery in mouse 
striatum. (A) RT-qPCR analysis of AAV vector derived transgene mRNA. Punches were taken 1 month 
after intra-striatal injection of 3x1010 gc of AAV9 vectors encoding mIFN gene under P2-Int, hSyn1 or 
Ple88 promoters. (B) Western blot analysis of mIFN expression from striatal punches of injected sites 
as described in 3A. (C) Distribution of EGFP positive cells in the striatum one month after injection of 
AAV9-P2-Int-EGFP or AAV9-Ple88-EGFP vectors. An AAV9/P2-int-mIFN injected brain was used as a 
no-EGFP control. Corresponding magnified views of the areas marked with black boxes in the left panel 
are shown on the right. Scale bars represent 50m.  
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Figure 2.5: Transduction of neurons upon AAV9 mediated intracranial delivery. Double 
immunofluorescence staining identify EGFP expressing cells (green) as positive for the neuron marker 
NeuN (red). Sections were also stained with DAPI (blue) to identify cell nuclei (‘c’, ‘g’ and ‘k’). Figures in 
the right panel (‘d-mag’, ‘h-mag’ and ‘l-mag’) show the magnified versions of the merged images (‘d’, ‘h’ 
and ‘l’, respectively) of EGFP and NeuN staining. Scale bars represent 100m. 
  
26 
 
 
Histological analysis of microglia/macrophage activation and T cells infiltration 
in tumor-bearing brain after AAV9/P2-Int-mIFN treatment. 
 As tumor-associated microglia/macrophages (TAMs) and T cells are important 
components of the immune system shown to influence brain tumor growth129-131 we 
analyzed the presence of these cells in tumor bearing brains after treatment with 
AAV9/P2-Int-mIFN vector. Activated TAMs (amoeboid Iba1+ cells) were readily 
apparent in all tumor-implanted brains, both AAV treated as well as PBS treated, 
compared to brains without tumor, where we saw only resting Iba1+ cells. However, in 
AAV9/P2-Int-mIFN treated brains there were noticeably higher numbers of activated 
TAMs in the brain around the tumor border compared to the PBS treated control 
(Figure 2.6A). CD3+ T cells were present in AAV treated brains in normal brain 
parenchyma near the tumor border at an early time-point (day-26 after tumor 
implantation) in contrast to PBS treated controls where there was no evidence of 
CD3+ cells. However, CD3+ T cells were no longer found at the humane endpoint 
(day-38) for the AAV treated group (Figure 2.6B). Interestingly, we observed that at 
the time of T cell infiltration (day-26) the tumor size in AAV treated brains was 
markedly smaller when compared to PBS treated control and the treated tumors 
already showed considerable amount of cell death at the center (Figure 2.6C).    
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Figure 2.6: Histological analysis of mouse brains carrying GL261 tumors treated with AAV9/P2-
Int-mIFN  
Representative brain sections immune-stained with antibodies to (A) Iba1 or (B) CD3 to detect the 
presence of tumor-associated microglia/macrophages and T cells, respectively. Corresponding 
hematoxylin-eosin stained sections are shown on the right (C). Top row shows brains that received 
PBS in place of tumor cells and treatment. Bottom three rows show animal brains that received PBS or 
AAV9/P2-Int-mIFN seven days after tumor implantation, and collected at day-26, or at the respective 
humane endpoint. White discontinuous lines indicate the border between tumor and normal brain. The 
letter ‘T’ indicates the tumor side of the border. Asterisks indicate the site of extensive cells death after 
treatment. Arrows point to the Iba1+ cells and arrowheads point to the CD3+ cells. Scale bars represent 
100m. Abbreviation: d, days post tumor implantation. 
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AAV9/P2-Int-mIFN and temozolomide combination therapy improves survival 
over each treatment modality alone. 
 Temozolomide (TMZ) is the standard-of-care chemotherapeutic drug used in 
conjunction with radiation following neurosurgical resection. Here we sought to 
determine if the combination of AAV9/P2-Int-mIFN with TMZ has increased potency 
compared to each therapy alone. However as TMZ compromises DNA replication, 
which is necessary for conversion of AAV to a transcriptionally active double stranded 
genome, it is possible that the combination would compromise the therapeutic effect of 
IFN gene therapy. To assess this possibility, two regimens were tested where 
GL261-implanted animals were treated with TMZ for five consecutive days starting 3 
days before (regimen-1) or 3 days after (regimen-2) AAV treatment. Two doses 
(1x1010 or 3x1010 gc) of AAV9/P2-int-mIFN were tested. Regimen-1 provided no 
survival benefit compared to either modality alone (Figure 2.7A), while the 
combination of TMZ and AAV in regimen-2 provided significant improvement in 
survival (Figure 2.7B). In regimen-2 the median survival for TMZ or AAV9/P2-Int-
mIFN (at 3x1010 gc) alone was 34 and 38 days, respectively, while the median 
survivals for the combination therapy was 41 days and 55 days for AAV doses of 
1x1010 and 3x1010 gc, respectively. Overall, the median survival for combination 
therapy with TMZ regimen-2 and AAV9/P2-Int-mIFN at 3x1010 gc more than doubled 
the median survival of PBS+DMSO control group, where it was only 26 days. 
 Histopathological analysis of the brains in the TMZ and AAV combination 
groups showed extensive cell death at the tumor center compared to TMZ-only treated 
groups (Figure 2.7C).  In addition there were considerably more activated TAMs  
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Figure 2.7. Combination of AAV9/P2-Int-mIFN with temozolomide improves therapeutic 
efficacy. (A-B) Schematic diagram of experimental paradigms (top) and Kaplan-Meier survival curves 
(bottom) for the therapeutic efficacy study of AAV9/P2-Int-mIFN and temozolomide (TMZ) combined 
treatment. Two TMZ regimens were tested: Daily 2.5mg TMZ administered from day-4 to day-8 in 
regimen-1 (reg1), or day-10 to day-14 in regimen-2 (reg2). Diluted DMSO (1:3 in PBS) was used as 
control for TMZ and PBS was used as control for AAV treatment. The survival curve for the (PBS + 
diluted DMSO) control group (black line) was used for comparison both in 5A and 5B. Log-rank test 
results: *p<0.05; **p<0.01. Animals per group (n) = 5. (C) Hematoxylin-Eosin staining of GL261 tumor 
bearing mouse brains at the humane endpoints. Asterisks indicate the site of extensive cells death after 
treatment. (D) Images show brain sections stained for the microglia marker Iba1. White discontinuous 
line indicates the border between tumor and normal tissue. The letter ‘T’ indicates the tumor location. 
The scale bars represent 100m. Abbreviations: reg, TMZ dose regimen; d, days post tumor 
implantation.  
30 
 
 
  
(amoeboid Iba1+ cells) in the brain around the tumor in the combination treatment 
groups compared to the ones treated with TMZ alone (Figure 2.7D).   
Intracranial AAV-mIFN treatment causes marked demyelinating neurotoxicity in 
the healthy mouse brains and body weight loss in some groups 
Here we tested the long term safety of intracranial AAV-mIFN treatment in 
healthy C57BL6/J mouse brains using the therapeutic dose (at 3x1010 gc). 
AAV9/Ple88-mIFN and AAV9/hSyn1-mIFN treated groups showed significant body 
weight loss 56 days post injection and had to be euthanized (Figure 2.8A). Histological 
analysis of the brains using hematoxylin-eosin and luxol fast blue staining showed 
enlarged vasculature and some loss of myelin (Figure 2.8B). AAV9/P2-Int-
mIFN treated group animals did not show any body weight loss or any abnormality in 
exterior appearance (data not shown) and survived for the full period of the study (100 
days) (Figure 2.8A). However, histological analysis showed marked progressive 
demyelinating neurotoxicity (figure 2.8B-D).         
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Figure 2.8. Continuous expression of mIFN results in toxicity in mouse brain. (A) Schematic 
diagram of experimental designs (top) and Kaplan-Meier survival curves (bottom) for the safety study in 
healthy mouse. AAV9 vectors encoding mIFN gene under different promoters, P2-Int (red), hSyn1 
(blue) or Ple88 (green), were injected in the striatum of healthy C57B6 mice. (B) Histological analysis of 
mouse brains injected with AAV9 vectors encoding mIFN at day-56 (humane endpoint for hSyn1 and 
Ple88 groups). Left two columns show images of hematoxylin-eosin stained brain sections. Right two 
columns show images of LFB staining for myelin. Black arrow point to enlarged blood vessels. Images 
of contralateral side (un-injected side) of the brains from the same animals are shown as controls. 
Scale bars represent 100m. (C) LFB staining of coronal brain sections of animals injected with 
AAV9/P2-int-mIFN. Animals were euthanized 100 days after AAV injection (study endpoint). Black 
arrows indicate the injection site where demyelination is observed. (D) High magnification images of the 
brains as described in 6C. Left column shows images of hematoxylin-eosin staining and right column 
shows LFB staining for myelin. Scale bars represent 100m. Abbreviations: d, days after AAV 
injection; LFB, luxol fast blue; H&E, hematoxylin and eosin.  
32 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER III: Gene therapy for highly invasive glioblastoma 
with systemic delivery of AAV9-IFN 
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Abstract  
 
 
In this section, we investigated the therapeutic effectiveness of systemically infused 
AAV9-hIFN against an invasive orthotopic GBM8 model. Systemic infusion of scAAV9-
hIFN vector induced complete regression of established GBM8 tumors in a dose-
dependent manner. The efficacy of this approach was also dependent on the stage of 
tumor growth at the time of treatment. We also show that peripherally produced hIFN 
contributed considerably to the therapeutic effect of scAAV9-hIFN. A comparative study 
of systemic and unilateral intracranial delivery of scAAV9-hIFN in a bilateral GBM8 
tumor model showed the systemic route to be the most effective approach to treat widely 
dispersed tumors. We thereby show that systemic delivery of AAV9-IFN is an attractive 
approach for highly invasive and distant multifocal glioblastoma treatment. 
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Results 
 
Dose dependent therapeutic response with systemic delivery of 
scAAV9/CB-hIFN 
To assess the therapeutic effectiveness of systemically delivered scAAV9/CB-
hIFN athymic nude mice were treated with different vector doses (1x1011, 3x1011 and 
1x10
12
gc), or PBS, two weeks after GBM8-Fluc tumor implantation. We measured 
tumor-associated bioluminescence signal (TABS) by live bioluminescence imaging to 
gain some insight into changes in tumor growth kinetics in mouse brain after AAV 
treatment. In PBS-injected control mice TABS increased exponentially until the animals 
reached the humane endpoint defined by >15% loss in maximum body weight. In the 
two top doses of scAAV9/CB-hIFN TABS decreased over time and was 
indistinguishable from baseline (week-1 signal) by 2 weeks after treatment (4 weeks 
after tumor implantation). This remained unchanged over time (Figure 3.1A-B). 
Treatment with 1x10
11
gc showed partial response. TABS decreased to baseline levels in 
two mice while in three mice in the group it increased over time albeit with a different 
kinetics than in the PBS control group (Figure 3.1B). 
The scAAV9/CB-hIFN dose-response was also reflected in long-term survival with 
100%, 88.89% and 20% of animals alive at 244 days post-tumor implantation in 
1x10
12
, 3x10
11 and 1x10
11
gc dose groups, respectively (Figure 3.1C). All animals from 
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the PBS control group reached the humane endpoint between 42-49 days with a median 
survival of 46 days after tumor implantation. 
 
Histological analysis of the brains from animals that survived to 244 days revealed 
normal histology with no microscopic evidence of tumors (Fig 3.1D, 3.2). Interestingly, in 
animals that succumbed to disease progressions in the 1x1011gc group, there were 
large tumors with sharply defined borders to normal tissue and composed of numerous 
well defined tumorlets (arrows in Figure 3.1D). This is in contrast to the diffuse nature of 
GBM8 tumors in mouse brain found in the PBS control group (Figure 3.1D). 
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Figure 3.1: Systemic delivery of scAAV9/CB-hIFN produces dose-dependent therapeutic response 
in orthotopic GBM8 xenograft mouse model. (A) Bioluminescence imaging of tumor burden in 
representative mice from each group for weeks 2-6 after tumor implantation. Regions of interest (ROI) used 
for signal quantification are shown as red circles. (B) Tumor associated bioluminescence signal (TABS) was 
assessed weekly up to 16 weeks and represented as fold change over signal at 1 week after tumor 
injection. Data is shown as mean  SD. Black arrow on the x-axis indicates time of treatment. Treatment 
groups are represented as follows: 1x1012 gc (red), 3x1011 gc (blue), 1x1011 gc (green) and PBS control 
group (black); ‘s1’ and ‘s2’, non-respondent and respondent subgroups, respectively. For 1x1011 gc group, 
the TABS curves for complete (dark green) and partial (light green) responders are plotted separately. ‘n’, 
number of animals in the group. (C) Kaplan-Meier survival curves for different treatment groups show dose-
dependent survival benefit. Survival curves are identified as follows: 1x1012 gc (red), 3x1011 gc (blue), 1x1011 
gc (green) and PBS control group (black); ‘n’, number of animals in the group. Log Rank P values: 
****p<0.0001; ***p < 0.001. (D) Representative images of Hematoxylin and Eosin staining of mouse brain 
sections at the endpoints. Top row depicts representative brain sections from different dose groups. Bottom 
row shows the magnified views of the corresponding areas indicated as ‘a’, ‘b’, ‘c’ and ‘d’ in the top row. 
Black arrows point to tumorlets with distinct borders. The brains were collected at the humane endpoints on 
day-44 (PBS control) and day-111 (1x1011 gc), or at the study endpoint on day-244 (3x1011 gc and 1x1012 
gc). Scale bars represent 100m. 
37 
 
 
 
 
 
Figure 3.2: Systemic delivery of scAAV9/CB-hIFN produces dose-dependent therapeutic response 
in orthotopic GBM8 xenograft mouse model. Immunohistochemical staining for oligodendrocyte 
transcription factor OLIG2 protein (glioblastoma stem cell marker) in the mouse brain from different dose 
groups. One representative picture is shown from each group (n=3). Scale bars represent 100m.  
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Therapeutic outcome is dependent on tumor growth phase at the time of 
treatment 
To assess the effect of tumor growth phase on the therapeutic efficacy 3x10
11
gc 
(minimum effective dose) of scAAV9/CB-hIFN was infused at 2, 3, 3.5 (~84 hours after 
week-3 treatment) and 4 weeks after GBM8-Fluc tumor implantation. Treatment at week-
2 and week-3 prevented tumor growth as suggested by TABS assessment over time 
(Figure 3.3A). This ultimately resulted in long-term survival of 100% and 88.9% of mice 
to 244 days after tumor implantation, respectively (Figure 3.3B). Treatment at 3.5 and 4 
weeks had a modest impact on TABS increase over time (Figure 3.3A). Nonetheless, it 
resulted in significant increases in median survival to 60 and 61 days, respectively, 
compared to 46 days for PBS control mice. The maximum survivals were increased to 
150 and 80 days, respectively, compared to 54 days for PBS controls (Figure 3.3B). 
 
 
Analysis of tumor burden by TABS at the treatment time points revealed that 
tumors remained largely unchanged between weeks 2 and 3, but increased thereafter 
(Figure 3.3C and 3.3D). Immunostaining of tumor sections for human nuclear antigen 
and GBM-specific OLIG2 marker at the time of treatment corroborated this observation 
(Figure 3.3E, 3.4). These results suggest a correlation between therapeutic efficacy of 
scAAV9/CB-hIFN vector treatment and tumor growth phase. 
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Figure 3.3. Treatment by systemic delivery of scAAV9/CB-hIFN before the onset of rapid tumor 
growth is critical for long-term survival benefit. (A) TABS is represented as fold-change over signal at 1 
week after tumor implantation. The timing of treatment (with 3x1011gc scAAV9/CB-IFN) after tumor 
implantation is identified as follows: 2nd week- (red), 3rd week- (purple), 3.5th week- (orange), 4th week- 
(green) treated and PBS control group (black) injected at 2nd week. Data is shown as mean  SD. Arrows 
of corresponding colors indicate the times of treatment for each group.  ‘n’, number of animals in the group 
(B) Kaplan-Meier survival curves showing effect of time of treatment on survival. Survival curves are 
shown for the same groups (with the same color coding) as for TABS change over time; ‘n’, number of 
animals in the group. Log-rank P values: ****p < 0.0001; ***p < 0.001. (C) Images of TABS in 
representative mice for each treatment time-point. Red circles are the regions of interest (ROI) for signal 
quantification. (D) Quantification TABS from imaging of live untreated GBM8-Fluc bearing mice at 
treatment time-points after tumor implantation. Each data-point on the plot is the TABS value from one 
mouse; Values are shown with group mean (black horizontal bar) and range (bars with different colors). 
Unpaired two-tailed t-test results: ** p<0.01; ns, not significant. (E) Representative images of untreated 
GBM8-Fluc bearing mouse brains immunostained for human nuclei at treatment time-points. 
Abbreviations: Str, left striatum, where tumor was implanted; W, weeks after tumor implantation. 
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Figure 3.4: GBM8-Fluc growth in brain at different treatment time-points (OLIG2 staining). Images of 
untreated GBM8-Fluc bearing mouse striatum (tumor implantation site) immunostained for OLIG2 protein at 
different treatment time-points. One representative picture is shown from each group (n=3). Scale bars 
represent 100m. Abbreviation: W, weeks after tumor implantation. 
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Systemically delivered AAV9 transduces primarily astrocytes and endothelial 
cells in the glioblastoma bearing mouse brain 
Tumor-bearing mice were injected systemically with 3x10
11
gc of scAAV9/CB-
EGFP vector to determine the cell types transduced and thus likely mediators of the 
therapeutic effect. Based on morphology (Figure 3.5A-B), it appears that most EGFP-
positive cells are astrocytes and endothelial cells found primarily in cortex and 
periventricular regions (Figure 3.5B) with fewer transduced cells in the striatum or tumor. 
These results suggest that, at its medium effective dose, the therapeutic effect of 
scAAV9/CB-hIFN is very likely achieved through expression of hIFN in normal 
astrocytes and vascular endothelia. 
 
Peripherally produced hIFN contributes to the therapeutic effect of systemically 
delivered scAAV9/CB-IFN 
As AAV9 transduces peripheral organs at high efficiency after vascular 
delivery125,132 and the ubiquitous nature of the CB promoter used in scAAV9/CB-INF it is 
possible that peripherally expressed hIFN contributes to the therapeutic effect against 
intracranial GBM8-Fluc tumors. Two AAV vectors were used to investigate this 
contribution: scAAV9/CB-hIFN-miRBS-1-122 (de-targeted) vector where CB-driven 
transgene expression was de-targeted from liver, muscle and heart by insertion of miR-1 
and miR-122 binding sites into the transgene cassette as described125; in scAAV9/TBG-
hIFN (TBG) vector transgene expression is driven by the liver-specific thyroxin binding 
globulin (TBG) promoter126. The therapeutic efficacy of these AAV9 vectors was  
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Figure 3.5: Astrocytes and vascular endothelial cells are the predominant brain cells transduced 
upon vascular delivery of scAAV9-EGFP vector in GBM tumor-bearing mice. (A) Representative 
pictures of immunohistochemical staining for EGFP expressing cells in brain sections from GBM8-Fluc 
bearing mice 3 weeks after tail vein delivery of 3x1011gc/mouse of scAAV9/CB-EGFP, scAAV9/TBG-EGFP, 
and control mice infused with PBS. 3,3’- diaminobenzidine (DAB) was used for detection of EGFP positive 
cells (brown) in the brain and hematoxylin counterstaining. (B) High magnification pictures of four different 
brain areas (identified in A by boxed small case letters) from mice injected with scAAV9/CB-EGFP vector 
Large arrows in ‘a’ and ‘c’ indicate EGFP expressing cells with astrocyte morphology. Small arrows in ‘b’ 
and ‘d’ indicate EGFP positive cells with vasculature morphology. Images from one representative animal 
from each group (n=3). 
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compared to scAAV9/CB-hIFN (CB vector) in GBM8-Fluc tumor bearing mice treated 
by systemic delivery.  The miR-1 and miR-122 regulation of AAV-CB-hIFN-miRBS-1-
122 transgene expression was validated first in cell culture (Figure 3.6).  Accordingly 
plasma concentration of IFN was significantly lower in mice treated with scAAV9/CB-
hIFN- miRBS-1-122 compared to scAAV9/CB-hIFN (Figure 3.7A). Also as expected 
vascular infusion of 3x10
11
gc of scAAV9/TBG-EGFP vector did not result in appreciable 
EGFP expression in brain (Figure 3.5A).  Both bioluminescence imaging and survival 
(Figure 3.7B-C) showed that treatment with de-targeted scAAV9/CB-hIFN-miRBS-1-
122 vector was less effective than scAAV9/CB-hIFN as it required 1x1012gc/mouse to 
achieve comparable suppression of tumor growth and 100% long-term survival. Vector 
genome copy analysis in brain, liver and skeletal muscle showed the two vectors to have 
comparable bio-distribution/transduction profiles (Figure 3.8). Therefore the ~3-fold 
lower therapeutic efficacy of the de-targeted vector could be due to differences in 
peripheral tissue expression of hIFN, or a difference in brain expression because of 
non-specific miRNA interaction, or both. Quantitative RT-PCR analysis of hIFN mRNA 
levels in brain showed comparable levels in mice treated with scAAV9/CB-hIFN and 
scAAV9/CB-hIFN-miRBS-1-122 vectors (Figure 3.7D). However hIFN mRNA levels 
were significantly reduced in liver and skeletal muscle of mice treated with scAAV9/CB-
hIFN-miRBS-1-122 compared to those infused with the same dose of scAAV9/CB-
hIFN  (Figure 3.7E-F). These results suggest that peripheral hIFN expression 
contributed substantially to the therapeutic efficacy of scAAV9/CB-hIFN. This 
conclusion is supported by the therapeutic results with liver-specific scAAV9/TBG-IFN 
where both doses tested changed the kinetics of GBM8-Fluc tumor growth (Figure 3.7B) 
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and improved survival significantly (Figure 3.7C), albeit less effectively than 
scAAV9/CB-IFN. The bio-distribution of scAAV9/TBG-IFN was comparable to the 
other vectors (Figure 3.8), but increased hIFN mRNA levels was found primarily in liver 
(Figure 3.7D-F). Nonetheless there was detectable hIFN mRNA present in the brain of 
mice treated with 1x10
12
gc of scAAV9/TBG-IFN albeit at > 2-log lower levels 
compared to the other two vectors (Figure 3.7D). 
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Figure 3.6: Functional testing of miR binding site regulation of hIFN expression in AAV plasmids. 
HEK 293T cells were transiently transfected with plasmids scAAV-CB-hIFN or scAAV-CB-hIFN-miRBS-1-
122 individually or in combination with plasmids coding for miR-1 or miR-122. An expression plasmid for 
gaussia luciferase (GLuc) was included to normalize for transfection efficiency. Conditioned media was 
collected 48 hours post-transfection and hIFN levels measured by ELISA. GLuc is a secreted protein and 
its activity was measured in the same conditioned medium. The columns represent the normalized values of 
hIFN in the media. Error bars indicate standard deviations. The experiment was done in triplicates. 
Unpaired two tailed t test was performed for statistical analysis; **p <0.01; ns, not significant difference in 
mean values. 
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Figure 3.7: Peripheral expression of hIFN contributes to the therapeutic effect of systemically 
infused scAAV9/CB-hIFN in the GBM8 mouse model. (A) scAAV9/CB-hIFN (CB) or scAAV9/CB-
hIFN-miRBS-1-122 (detargeted) vectors were infused at the shown doses, or PBS at 2 weeks after tumor 
implantation and plasma hIFN levels measured one month later by ELISA (n=4 per group). Columns 
represent mean values and error bars indicate standard deviation (SD). In unpaired two tailed t test, ****p 
<0.0001. (B) TABS kinetics represented as fold change over signal at one week after tumor implantation for 
all treatment groups. CB vector, detargeted vector or scAAV9/TBG-hIFN (TBG vector) were injected 2 
weeks after tumor implantation at shown doses. Data is shown as mean  SD. (C) Kaplan-Meier survival 
curves for different treatment groups. In Log-Rank test, **p<0.01; ns, not significant (p >0.05). (D-F) 
Comparison of hIFN mRNA levels in brain, liver and skeletal muscle in mice from different treatment 
groups at the humane or study endpoints by RT-qPCR (n=3 per group). Top panels show the comparative 
delta CT values and bottom panels show relative expression. Data is shown as mean  SD. In unpaired two 
tailed t test, *p <0.05; **p <0.01; ***p <0.001; ns, not significant (p >0.05). 
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Figure 3.8: Vector bio-distribution in different tissues. Total DNA (100 ng) from brain, skeletal muscle 
and liver was used to quantify vector genome content by quantitative PCR. Relative values were calculated 
to the vector genome content in each tissue from animals treated by systemic administration of 3x1011gc 
scAAV9/CB-hIFN. The number of animals per group (n) =3. Columns represent relative group mean values 
and error bars indicate standard deviations; ns, not significantly different in unpaired two tailed t test (p 
>0.05).  
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Systemic delivery of scAAV9-hIFN is more effective than local administration for 
treatment of multifocal GBM 
 
Previously we have shown that intracranial injection of AAVrh8-IFN vectors leads 
to complete regression of established non-migratory orthotopic human U87 brain 
tumors97. Here we sought to compare the effectiveness of local vs. systemic delivery of 
scAAV9/CB-hIFN in mice with bilateral GBM8-Fluc tumors to mimic multifocal 
recurrence. Mice were treated either by unilateral intracranial injection, or systemic 
administration of scAAV9/CB-IFN. 
 
Bioluminescence imaging showed (Figure 3.9A-B) that tumors grew uninhibited on both 
sides of the brain in the untreated control group (Figure 3.9A). The average right: left 
(R:L) TABS ratio for this group remained at 1.05 ± 0.11 over time (Figure 3.9B). In the 
group treated by unilateral intracranial injection, TABS decreased over time in the left 
(treated) hemisphere but it increased rapidly in the untreated right hemisphere (Figure 
3.9A). This was reflected in the increase in R:L TABS ratio over time (Figure 3.9B). In 
contrast, TABS decreased over time in both hemispheres and eventually became 
undetectable in mice treated systemically (Figure 3.9A), and the average R:L TABS ratio 
remained unchanged at 1.04± 0.11. The impact on survival was consistent with the 
tumor growth imaging data. The median survival of mice treated by unilateral intracranial 
injection of scAAV9/CB-IFN was 56 days compared to 43 days for untreated animals, 
but nonetheless all animals in this cohort succumbed to tumor growth. In contrast all 
animals in the systemic treatment group survived until the 8-month experimental 
endpoint (Figure 3.9C). 
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Histological analysis of brains at endpoint (Figure 3.9D) showed no evidence of 
residual tumors in mice treated systemically. In mice treated by unilateral intracranial 
injection, there were large tumor masses in the right (untreated) hemisphere, but unlike 
untreated tumors these had sharply defined tumor-brain parenchyma borders. This 
indicates that scAAV9/CB-IFN injection in the left hemisphere effectively prevented 
ipsilateral tumor growth, but it was insufficient to prevent distal tumor growth in the 
contralateral hemisphere. Nonetheless it appears that local treatment changed the 
phenotype of the untreated tumor in the contralateral hemisphere. 
 
Finally the presence of remnant GBM8-FLuc tumor cells was assessed in brain 
sections by immunostaining for oligodendrocyte transcription factor-2 (OLIG2) as this is 
a protein highly expressed in glioblastoma stem cells133,134. No OLIG2-positive cells 
were apparent in the brain of systemically treated mice, while the OLIG2 immunostaining 
patterns in the other two groups were consistent with the histological findings (Figure 
3.10). 
 
The present study shows that systemic scAAV9/CB-hIFN gene therapy is an 
effective approach to overcome the invasiveness and long distance migratory properties 
of glioblastoma. 
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Figure 3.9: Systemic delivery of scAAV9-hIFN vector is more effective than intraparenchymal 
administration for treatment of multifocal GBM. (A) Images of TABS over time (weeks 2-6) in 
representative mice with bilateral GBM8-Fluc tumors treated by systemic (3x1011 gc) or unilateral (left 
tumor) intracranial (7.6x109 gc) administration of scAAV9/CB-hIFN vector. Separate regions of interest 
(ROI; red boxes) over the left and right side of the head were used to quantify TABS for each bilateral 
tumor. (B) Change in right to left hemisphere (R/L) TABS ratio from week 1 to week 6 after tumor 
implantation in mice treated by systemic (green line) or unilateral intracranial injection (red line), and 
untreated controls (black line). All values are normalized to the week-1 signal (n=5 mice per group) (C) 
Kaplan-Meier survival curves for mice treated by systemic (green line), or unilateral (left tumor) intracranial 
(red line) delivery of scAAV9/CB-hIFN vector and untreated control group (black line) (n=5 mice per 
group). (D) Representative pictures of brain sections stained with hematoxylin and eosin from different 
groups at the humane (Untreated: day 43 and unilateral intracranial treatment: day 56) or study endpoint 
(day 244). On the left most panel whole brain sections are shown at low magnification. On the right two 
panels, high magnification images are shown of the corresponding areas indicated in the whole brain 
sections by L1, L2 or L3 and R1, R2 or R3. Scale bars represent 100m. 
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Figure 3.10: Systemic delivery of scAAV9-hIFN vector is more effective than intraparenchymal 
administration for treatment of multifocal GBM (OLIG2 staining).  Immunohistochemical staining for 
OLIG2 protein expression in the mouse brain from different groups. One representative picture is shown 
from each group (n=3).  
  
52 
 
 
Discussion 
Studies in the past have demonstrated the anti-tumor potential of IFN protein on 
glioblastoma ranging from cell culture studies135 to clinical trials118. But the short half-life119 
of recombinant IFN is a major limiting factor in achieving greater therapeutic benefit. 
Gene therapy is an attractive approach to overcome this limitation. Several studies from 
our group96,97 and others95,98 have demonstrated the potential of IFN gene therapy for 
glioblastoma. But none of these studies has tested this approach in an orthotopic 
glioblastoma model that is also truly invasive in nature. The study reported in Chapter II, 
to the best of our knowledge, is the first that shows that local IFN gene therapy can 
effectively treat highly invasive human glioblastoma in an orthotopic mouse xenograft 
model. This is also the first study where long-term survival benefit was achieved in a 
highly invasive glioblastoma model using only a single local intracranial injection of AAV 
vectors. An interesting finding was that in week-4 treated animals that succumbed to 
disease progression had tumors with distinct borders unlike the diffuse pattern observed 
for these invasive GBM8 tumors in PBS treated control animals (Figure 2.1E). This 
suggests that IFN may have anti-migratory properties, but further studies are necessary 
to investigate this unusual finding. 
With a similar therapeutic approach we also assessed the therapeutic potential of AAV-
IFN gene therapy in a syngeneic mouse glioblastoma model. As IFN interacts with its 
receptor in a species specific manner for its anti-proliferation effect121, we used mouse 
IFN for treatment of this mouse tumor. A critical aspect was to design an AAV-mIFN 
vector for optimal expression of IFN to reduce the risk of possible detrimental side 
53 
 
 
effects, as became apparent for a subset of AAV vectors where survival of treated animals 
was shorter than controls (Figure 2.3). Nonetheless the screening process identified 
several AAV9 vectors that provided moderate survival benefit and the histological 
appearance of tumors in AAV treatment groups with large centers devoid of cells indicate 
that mIFN expression had a potent biological effect on the tumor. In control group, 
animals reached the humane endpoint likely because of the large tumor masses that 
occupy a substantial fraction of the ipsilateral hemisphere. However the demise of AAV 
treated animals may have been caused by the combined effect of residual tumor 
mass/size and an inflammatory response triggered either by a direct effect of mIFN on 
microglia or by tumor cell death. Apparently exposure of microglia to IFN triggers the 
secretion of neuroinflammatory mediators (TNF, IL-1, IL-6, or nitric oxide)136. This can 
potentially have detrimental effects on the nervous system in a mouse, which in turn could 
result in body weight loss in the long term and thus forcing humane euthanasia. This was 
corroborated by the finding in the safety study where we saw demyelinating neurotoxicity 
in AAV-mIFN treated healthy mouse brains (Figure 2.8). 
The notion that an inflammatory response may have been triggered by AAV- 
mIFN treatment is supported by the increase in activated microglia (amoeboid Iba1+ 
cells) around tumors in treatment groups compared to controls (Figure 2.6A and 2.7C). 
Nonetheless gliomas are also known to secrete chemo-attractant molecules (CSF1, 
SDF1, CX3CL1 etc.) that attract microglia/macrophages137. Presently it is unknown how 
the increased numbers of tumor-associated microglia/macrophages (TAMs) associated 
with AAV-mIFN treatment affected tumor growth. This is because previous reports131,137  
have shown that glioma cells can polarize TAMs towards a pro-tumor phenotype that 
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eventually makes the tumor milieu favorable for proliferation and invasion. This could be 
one possible reason why AAV treated animals eventually succumbed to tumors. Even 
though we did not observe a noticeable change in the overall density of activated TAMs 
around AAV-mIFN treated tumors between early stage (day-26) and the humane 
endpoint (day-38), it is possible that the anti-tumor vs pro-tumor polarization status of the 
population changed over time in favor of the latter. In addition the immune suppressive 
properties of gliomas mediated through IDO1 expression and induction of regulatory T 
cells (Treg)130,138,139, may have been responsible for what appears to be the disappearance 
of CD3+ T cells from the vicinity of the tumor between day-26 and day-38 (Figure 2.6B). 
Next, we have shown that AAV-mIFN gene therapy can be applied in tandem with 
the current standard care temozolomide treatment to significantly improve the survival 
benefit. Interestingly, we have observed that the temporal order of temozolomide and AAV 
treatment is an important factor in determining the added benefit from the combined 
therapy. We found that starting temozolomide prior to AAV abolished the potentiated 
therapeutic benefit observed when temozolomide was started 3 days after AAV injection 
(Figure 2.7A-B). Although we did not study the mechanistic details, one possible reason 
for this observation could be that DNA-alkylation caused by temozolomide interferes with 
the DNA synthesis necessary to generate transcriptionally active double stranded AAV 
genomes140.  Presently we are unable to rule out the possibility that TMZ may inhibit any 
cellular pathways necessary for productive AAV gene expression. While further studies 
are needed to uncover the exact mechanism, the potential effect of TMZ on AAV gene 
transfer to CNS is an important finding for any future therapies involving AAV gene 
delivery and DNA-alkylating agents. The detrimental effect of TMZ on AAV gene therapy 
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may not be a significant limitation in clinical practice as chemotherapy usually starts 4 
weeks after surgery in glioblastoma patients141,142 and thus local injection of AAV-IFN 
vectors in the brain tissue immediately after surgical resection of tumors would be a viable 
option.  
In Chapter III, we have successfully demonstrated that systemic delivery of AAV9-
IFN can engineer brain cells to form a global tumor inhibitory network, which can 
effectively treat an invasive GBM model. Besides, while our earlier study97 did show 
prevention of new tumor establishment in contralateral hemisphere in a pre-treatment 
model, it was unsuccessful in treating established contralateral tumors. In the current 
study, we show for the first time that systemic delivery can be therapeutically effective for 
such distant or multifocal tumors. The limitation of intraparenchymal infusion of AAV 
vectors to treat widespread GBM tumors was also apparent here, albeit in the context of 
an artificial model of concurrent bilateral tumors. These results are consistent with a 
recent study where intracranial injection of an AAVrh8-sTRAIL vector extended survival of 
mice with GBM8 tumors, but ultimately all animals succumbed to tumor growth in <100 
days143. 
 Interestingly, in this study although distal intracranial injection was insufficient to 
achieve regression of established GBM8 tumors, it modified the histological phenotype of 
the invasive GBM to one of a non-invasive tumor (Figure 3.9D, 3.10). This is evident from 
the distinct border noticeable between tumor and non-tumor tissues in contrast to the 
diffuse pattern seen in the untreated control group. A similar effect on tumor phenotype 
was documented in mice treated systemically with the sub-optimal dose (1x1011gc) of 
scAAV9/CB-hIFN (Figure 3.1D) and also in late treatment group with intracranial delivery 
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in Chapter II (Figure 2.1E). These observations together suggest that AAV-IFN 
treatment, even at a sub-therapeutic level, could be useful to prevent tumor invasion in the 
surrounding tissues, and thus making it relatively easier to be eliminated by surgical 
resection. Presently the mechanism of low-level IFN induced switch from a migratory to a 
local rapidly dividing phenotype is unknown, but further studies may reveal new targets in 
the molecular networks that regulate GBM migration and invasion144-146. 
           A previous study reported some therapeutic effect of a systemically delivered AAV8 
vector encoding IFN in U87 tumors grown in the flank of mice98. However flank GBM 
xenografts do not reproduce the challenges of brain gene delivery, systemically or 
otherwise. To our knowledge this is the first study showing that systemic delivery of AAV9-
IFN induces complete regression of tumors in a highly invasive orthotopic glioblastoma 
model.  
             We have used an immune-compromised athymic mouse model for this study 
which lack T cells. Moreover, as human IFN does not interact with the mouse IFN 
receptors121 it is unlikely that mouse innate immune cells would be induced by human 
IFN as was also indicated in a previous study64. Therefore the therapeutic effect 
documented for the xenograft model is possibly due to a direct effect of IFN on GBM8 
tumor cells.  
              In this part of the study, we observed that gene transfer efficiency in the tumor or 
surrounding striatum was noticeably low compared to cortex or periventricular region. 
Nonetheless it appears that expression of IFN from normal cells in the brain and to some 
extent from peripheral tissues contributed to the therapeutic benefit. However, due to 
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technical difficulties (such as, high background noise in the ELISA protein estimation from 
the brain homogenate and lack of highly sensitive antibodies to detect IFN at low 
quantities in the western blot) we could not directly measure the human IFN protein level 
in the brain or cerebrospinal fluid after treatment with different vectors. The therapeutic 
effect documented in this study lends support to the notion of exploring systemic AAV 
gene therapy encoding secretory proteins with anti-tumor properties (e.g. interferon alpha, 
tumor necrosis factor alpha, TNF-related apoptosis inducing ligand) given that widespread 
direct tumor cell transduction may be challenging. 
Concluding remarks 
The studies with local AAV-IFN treatment approach reported in Chapter II have 
been successful to provide long-term survival in the invasive human GBM xenograft 
model and more than doubled the median survival in the syngeneic GL261 mouse tumor 
model when used in combination with temozolomide therapy. In Chapter III we showed 
that systemic delivery approach has a tremendous potential for treating distant multifocal 
and highly invasive GBM. Even though there is a considerable risk factor associated with 
IFN mediated neurotoxicity in the long term continuous expression, considering that the 
median survival of glioblastoma patients is very short with the current standard-of-care 
treatment, the therapeutic benefit shown for intracranial AAV-IFN therapy would be a 
significant improvement. For systemic delivery approach we need to be further cautious 
though for possible additional toxicity from peripheral organ. However, the reward to risk 
ratio of this gene therapy approach may be further improved by fine-tuning IFN 
expression using transcriptional and post-transcriptional regulation to make transgene 
expression more specific for tumor cells or tumor microenvironment147-149. Use of 
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switchable promoters150 could be an option to avoid possible toxicity from long term 
continuous expression of IFN and co-treatment of phosphodiesterase inhibitors could 
potentially minimize the possible neuro-inflammatory side effects of IFN treatment136.
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